

*Annual Review of Physiology*

# Physiological Functions of CRAC Channels

Scott M. Emrich,<sup>1</sup> Ryan E. Yoast,<sup>1</sup>  
and Mohamed Trebak<sup>1,2</sup>

<sup>1</sup>Department of Cellular and Molecular Physiology, Pennsylvania State University College of Medicine, Hershey, Pennsylvania, USA; email: trebakm@pitt.edu

<sup>2</sup>Department of Pharmacology and Chemical Biology and Vascular Medicine Institute, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA

Annu. Rev. Physiol. 2022. 84:355–79

First published as a Review in Advance on  
October 12, 2021

The *Annual Review of Physiology* is online at  
physiol.annualreviews.org

<https://doi.org/10.1146/annurev-physiol-052521-013426>

Copyright © 2022 by Annual Reviews.  
All rights reserved

ANNUAL  
REVIEWS **CONNECT**

[www.annualreviews.org](http://www.annualreviews.org)

- Download figures
- Navigate cited references
- Keyword search
- Explore related articles
- Share via email or social media

## Keywords

Ca<sup>2+</sup> signaling, store-operated Ca<sup>2+</sup> entry, SOCE, CRAC channels, STIM, Orai, physiology, disease

## Abstract


Store-operated Ca<sup>2+</sup> entry (SOCE) is a ubiquitous Ca<sup>2+</sup> signaling pathway that is evolutionarily conserved across eukaryotes. SOCE is triggered physiologically when the endoplasmic reticulum (ER) Ca<sup>2+</sup> stores are emptied through activation of inositol 1,4,5-trisphosphate receptors. SOCE is mediated by the Ca<sup>2+</sup> release-activated Ca<sup>2+</sup> (CRAC) channels, which are highly Ca<sup>2+</sup> selective. Upon store depletion, the ER Ca<sup>2+</sup>-sensing STIM proteins aggregate and gain extended conformations spanning the ER–plasma membrane junctional space to bind and activate Orai, the pore-forming proteins of hexameric CRAC channels. In recent years, studies on STIM and Orai tissue-specific knockout mice and gain- and loss-of-function mutations in humans have shed light on the physiological functions of SOCE in various tissues. Here, we describe recent findings on the composition of native CRAC channels and their physiological functions in immune, muscle, secretory, and neuronal systems to draw lessons from transgenic mice and human diseases caused by altered CRAC channel activity.

## INTRODUCTION

The physiological function of all eukaryotic cells is regulated by intracellular calcium ( $\text{Ca}^{2+}$ ).  $\text{Ca}^{2+}$  is indispensable as a secondary messenger that regulates a diverse array of cellular processes, including fertilization, immunity, contraction, metabolism, transcription, and apoptosis (1–5). Although essential in all tissue types, cytosolic  $\text{Ca}^{2+}$  must be maintained at extremely low concentrations ( $\sim 100$  nM) relative to the enormous concentration in the extracellular milieu ( $\sim 1$ – $2$  mM). Altered  $\text{Ca}^{2+}$  homeostasis and  $\text{Ca}^{2+}$  overload are implicated in a wide variety of inflammatory, neurological, and metabolic disorders (6–8). To maintain this steady state, cells utilize an exquisite array of ion channels, transporters, and exchangers to store  $\text{Ca}^{2+}$  within the endoplasmic reticulum (ER) ( $300$   $\mu\text{M}$ – $1$  mM) and pump excess  $\text{Ca}^{2+}$  out across the plasma membrane (PM) (1). The predominant mechanism of  $\text{Ca}^{2+}$  entry in nonexcitable cells is through the ubiquitous store-operated  $\text{Ca}^{2+}$  entry (SOCE) pathway, first recognized and formulated by Jim Putney (9). SOCE involves a complex choreography between PM Orai channel proteins and ER-resident  $\text{Ca}^{2+}$ -sensing stromal interaction molecules (STIMs) (4, 5, 10). Stimulation of PM receptors coupled to isoforms of the phosphoinositide-specific phospholipase C (PLC) results in production of diffusible inositol 1,4,5-trisphosphate ( $\text{IP}_3$ ), which triggers release of ER  $\text{Ca}^{2+}$  through  $\text{IP}_3$  receptors ( $\text{IP}_3\text{Rs}$ ). The depletion of ER  $\text{Ca}^{2+}$  is sensed by STIM1 and its homolog STIM2, causing a conformational change of STIM proteins, which unmask their C-terminal STIM Orai-activating region/CRAC-activating domain (SOAR/CAD) (11, 12), and their translocation to ER–PM junctions where they trap and gate PM Orai channels to drive  $\text{Ca}^{2+}$  entry into the cell (1, 4, 5, 10) (**Figure 1**). The biophysical manifestation of STIM/Orai-mediated SOCE is the  $\text{Ca}^{2+}$  release-activated  $\text{Ca}^{2+}$  (CRAC) current,  $I_{\text{CRAC}}$  (13, 14).

The tissue-specific functions of CRAC channels have largely been informed by the identification of human patients with inherited loss-of-function (LoF) mutations in *Orai1* and *STIM1* (15–18). These patients manifest with a variety of symptoms, including severe combined immunodeficiency with reoccurring viral, bacterial, and fungal infections, autoimmunity, hemolytic anemia, ectodermal dysplasia with defective dental enamel development and anhidrosis, and muscle hypotonia (19). Patients with defective CRAC channel function were identified in the 1990s, but the molecular identity of CRAC remained unknown for over a decade (20–22). Large-scale RNA interference (RNAi) screening against proteins with conserved  $\text{Ca}^{2+}$  signaling domains first led to the identification of STIM1 (23, 24). Genome-wide RNAi screening and genetic linkage analysis discovered the identity of Orai1 (17, 25, 26). These landmark findings have since led to the development of new transgenic animal models to understand the function of CRAC channels in physiology and pathophysiology (5). It is now well established that Orai1 is an essential subunit of the native CRAC channel and that Orai1 and STIM1 contribute to SOCE in most primary tissue types that have been investigated (27, 28).

Although the physiological functions of Orai1 and STIM1 have been the subject of intense study over the past 15 years, vertebrates have evolved a second STIM protein, STIM2, and two additional Orai isoforms encoded by independent genes. *STIM2* and *Orai2* genes are found in all vertebrates, whereas the *Orai3* gene is exclusive to mammals, potentially duplicating from the *Orai1* gene (29). Extensive work has demonstrated that Orai2 and Orai3 are highly homologous to Orai1 and that both homologs form functional CRAC channels when ectopically expressed with STIM1, albeit with distinct biophysical properties (30, 31). Despite Orai2 and Orai3 mRNAs being ubiquitously expressed, the role these channels play under native conditions has largely remained obscure. There are currently no reported patient mutations in either *Orai2* or *Orai3* genes that are associated with disease. Further, the lack of reliable antibodies, channel potentiators, or inhibitors that can distinguish between Orai isoforms has hampered our understanding of the





**Figure 1**

Activation of CRAC channels. Binding of agonists to their specific PLC-coupled receptors in the PM leads to production of IP<sub>3</sub> and release of Ca<sup>2+</sup> from ER stores. ER store depletion activates STIM proteins, which translocate to ER–PM junctions where they trap and gate CRAC channels composed of hexameric Orai subunits. Native CRAC channels are likely heterohexamers of Orai1/2/3 isoforms with varying potencies. Different STIM homodimers or heterodimers work together to activate or inhibit (e.g., STIM2.1) CRAC channels, thus fine-tuning their activity. Resting STIMs tonically inhibit IP<sub>3</sub>Rs. This complex choreography between STIM/Orai/IP<sub>3</sub>Rs ensures that Ca<sup>2+</sup> release, Ca<sup>2+</sup> entry, and NFAT activation are coordinated and tailored to the concentration of agonist and level of store depletion. Abbreviations: CaM, calmodulin; CRAC, Ca<sup>2+</sup> release-activated Ca<sup>2+</sup>; DAG, diacylglycerol; ER, endoplasmic reticulum; GPCR, G protein-coupled receptor; IP<sub>3</sub>R, inositol 1,4,5-trisphosphate receptor; MCU, mitochondrial Ca<sup>2+</sup> uniporter; NCLX, Na<sup>+</sup>/Ca<sup>2+</sup>/Li<sup>+</sup> exchanger; NFAT, nuclear factor of activated T cells; PLC, phospholipase C; PM, plasma membrane; PMCA, plasma membrane Ca<sup>2+</sup> ATPase; PtdIns(4,5)P<sub>2</sub>, phosphatidylinositol 4,5-bisphosphate; RTK, receptor tyrosine kinase; SERCA, sarco-/endoplasmic reticulum Ca<sup>2+</sup>-ATPase; STIM, stromal interaction molecule.

physiological functions of Orai2 and Orai3. Similarly, small interfering RNA (siRNA) knockdown approaches used in earlier studies largely failed to identify significant contributions of either Orai2 or Orai3 to native SOCE induced by maximal store depletion, except for Orai3 in subsets of cancer cells (32, 33).

Nevertheless, knockout mice and CRISPR/Cas9 gene knockout in cell lines have shed light on the role of Orai2 and Orai3 within the native cellular context. Global Orai2 knockout mice and cell lines devoid of each Orai isoform individually and in combination have provided strong evidence that Orai2 and Orai3 form heteromeric CRAC channels with Orai1 and negatively regulate native CRAC channel activity (34–37). Within the native CRAC channel hexamer, current evidence supports a model whereby Orai2 and Orai3 negatively regulate Orai1 function and expand the repertoire of receptor-stimulated Ca<sup>2+</sup> signaling events (**Figure 2**). This reflects the enhanced



**Figure 2**

Multiple Orai and STIM isoforms underlie the diversity of  $Ca^{2+}$  signaling events. Orai1 (*a*) and STIM1 (*b*) mediate the majority of SOCE in response to maximal store depletion, whereas Orai2/3 are negative regulators (*a*). (*c,d*) In response to agonist stimulation, cells lacking either Orai1 or STIM1 cannot support SOCE plateaus, and cells lacking either Orai2/3 or STIM2 develop plateaus at lower agonist concentrations and thus have a reduced bandwidth of  $Ca^{2+}$  signaling events. (*e*) Orai1 and STIM1 are sufficient to support SOCE, but the graded diversity of  $Ca^{2+}$  oscillatory frequencies is largely reduced (on/off switch). Involvement of various STIM isoforms and splice variants and that of homo- and heterohexameric CRAC channels made of combinations of Orai isoforms support the graded diversity of mammalian  $Ca^{2+}$  signaling events (dimmer switch). Abbreviations: CRAC,  $Ca^{2+}$  release-activated  $Ca^{2+}$ ; KO, knockout; SOCE, store-operated  $Ca^{2+}$  entry; STIM, stromal interaction molecule.

interaction of both Orai2 and Orai3 with STIM1 under conditions where ER  $\text{Ca}^{2+}$  stores are replete, as well as the enhanced fast  $\text{Ca}^{2+}$ -dependent inactivation of these two isoforms (36, 38). Thus, different heteromeric combinations of the Orai isoform trio provide a robust mechanism to fine-tune SOCE by matching the strength of agonist stimulation to downstream  $\text{Ca}^{2+}$  signaling events (**Figure 2**). Although the precise Orai heteromeric assembly or assemblies in any given cell type remain unknown, different CRAC heteromers are likely tailored to specific cell types and their respective functions. For instance, Orai1 is upregulated while Orai2 is downregulated in effector T cells in comparison to naïve T cells (35). Orai2-mediated inhibition of CRAC channel activity in naïve T cells likely prevents unwanted activation of those naïve T cells. Unlike Orai1 and Orai2, Orai3 is resistant to oxidant-mediated inhibition (39, 40), and some cancer cells remodel to signal through Orai3 (33, 41–43), likely as a mechanism to maintain channel activity in hypoxic or oxidant-rich tumor environments.

Similarly, new findings have further clarified the physiological function of STIM2. While earlier studies characterized STIM2 as an essential regulator of basal ER and cytosolic  $\text{Ca}^{2+}$  levels (44), recent evidence suggests that STIM2 is an active participant in SOCE across the full spectrum of agonist strengths (45). STIM2 plays a critical role in STIM1 recruitment to drive efficient activation of Orai1 at low agonist intensities (46, 47). Recent studies have also revealed that STIM2 is a major contributor to SOCE in specific cell types, including neurons (48), colorectal carcinoma cells (49), and NIH T3T fibroblasts and the gonadotropic cell line  $\alpha\text{T}3$  (50). STIM1 and STIM2 coordinate across a range of agonist concentrations for optimal activation of nuclear factor of activated T cells (NFAT) (45, 49, 50). Emrich et al. (45) showed that while activated STIM proteins interact with Orai to stimulate  $\text{Ca}^{2+}$  entry, unactivated STIMs inhibit  $\text{IP}_3\text{Rs}$ , thus tailoring  $\text{Ca}^{2+}$  release to  $\text{Ca}^{2+}$  entry (**Figure 1**). Interestingly, a widely expressed STIM2 splice variant, STIM2.1 (also called STIM2 $\beta$ ), was identified. STIM2.1 is a potent negative regulator of SOCE in several cell types, including  $\text{CD}4^+$  T, Jurkat, HEK293, and C2C12 cell lines (51, 52). STIM2.1 inhibits Orai1 channel clustering, agonist-induced  $\text{Ca}^{2+}$  oscillations, and myogenesis (53, 54). As discussed in detail below, STIM1 has a long splice variant called STIM1L that is found in skeletal muscle (55). Recently, Ramesh et al. (56) identified a short splice variant of STIM1 that is exclusive to neurons, called STIM1B. STIM1B locates to presynaptic sites and mediates CRAC currents with slower kinetics and reduced inactivation that support short-term synaptic enhancement during high-frequency neuronal stimulation (56).

In summary, while both STIM1 and Orai1 are undoubtedly the major components of the canonical SOCE pathway, their combined function represents only a narrow window of the diverse  $\text{Ca}^{2+}$  signaling events (**Figure 2**). It is becoming apparent that all five Orai and STIM members and their splice variants, along with  $\text{IP}_3\text{Rs}$  and likely other regulatory proteins, continuously operate in a harmonious manner to shape the diversity of the physiological  $\text{Ca}^{2+}$  signal in response to the graded concentrations of agonist encountered by cells in vivo. Below, we seek to highlight new research on the role of SOCE in physiology and disease, within the context of this dynamic model of STIM/Orai isoform interactions. We discuss how SOCE function is tailored to different tissue systems and regulates diverse cellular functions, including proliferation, secretion, contraction, differentiation, development, and metabolism.

## IMMUNE SYSTEM

### T Cells

In T cells,  $\text{Ca}^{2+}$  influx through CRAC channels is required for the activation of the calcineurin/NFAT pathway, subsequent IL-2 secretion and clonal expansion (1). One of the major phenotypes of patients with LoF mutations in *Orai1* or *STIM1* is severe combined

immunodeficiency coupled with autoimmune disease, including hemolytic anemia, thrombocytopenia, lymphadenopathy, and hepatosplenomegaly (28). The role of SOCE in T cell function has been extensively reviewed elsewhere (1, 3, 57, 58). Below, we highlight critical progress within the field grouped into three broad categories: (a) molecular makeup of native CRAC channels in T cells, (b)  $\text{Ca}^{2+}$ -mediated regulation of T cell metabolism, and (c) the functions of SOCE in specific T cell subsets.

**CRAC makeup in T cells.** In patients with the R91W LoF mutation in *Orai1*, T cells display a complete loss of SOCE and  $I_{\text{CRAC}}$  (15–17). Of note, residual SOCE is observed in B cells from patients with LoF in *Orai1* (21). Curiously, SOCE in T cells isolated from global *Orai1*<sup>-/-</sup> mice on the mixed Institute of Cancer Research (ICR) background, CD4<sup>+</sup> T cell-specific knockout (*Orai1*<sup>fl/fl</sup>Cd4<sup>cre</sup>) mice, or *Orai1*<sup>R93W</sup> knock-in mice (equivalent of human R91W) is only partially attenuated, suggesting that *Orai2* and/or *Orai3* mediate the residual SOCE in mouse T cells (35, 59, 60). Surprisingly, SOCE in naïve, but not effector, *Orai2*<sup>-/-</sup> T cells was enhanced while *Orai1*<sup>-/-</sup> *Orai2*<sup>-/-</sup> T cells displayed a near complete loss of SOCE (35).  $I_{\text{CRAC}}$  was increased in *Orai2*<sup>-/-</sup> bone marrow-derived macrophages. Critically, ectopic expression of pore-dead mutants for either *Orai1* (E106Q) or *Orai2* (E80Q) blocked native SOCE in *Orai1*<sup>-/-</sup> or *Orai2*<sup>-/-</sup> T cells, suggesting that *Orai1* and *Orai2* form heteromeric CRAC channels. *Orai1*<sup>fl/fl</sup>Cd4<sup>cre</sup>/*Orai2*<sup>-/-</sup> double knockout mice show impaired regulatory T cell development and reduced germinal center (GC) formation in response to viral infection. Adoptive transfer of *Orai1*<sup>-/-</sup> *Orai2*<sup>-/-</sup> T cells into immune-deficient mice also failed to induce colitis or graft-versus-host disease (35). These data on *Orai2*<sup>-/-</sup> T cells is in agreement with results from *Orai2*-deficient mast cells, *Orai2* knock-down human chondrocyte and neuroglioma cell lines, and *Orai2* knockout HEK293 cells, where SOCE is also enhanced (34, 36, 61, 62). Cumulatively, these studies identify *Orai2* as a robust negative regulator of *Orai1* channel function. In addition to its role as a negative regulator of native CRAC channels, *Orai3* was proposed as a component of an *Orai1*/*Orai3* heteromeric channel activated independently of store depletion by arachidonic acid and its metabolite, leukotriene C<sub>4</sub>, and termed arachidonate-regulated  $\text{Ca}^{2+}$  (ARC) channel (38, 63–65). In contrast to *Orai1* and *Orai2*, the role of native *Orai3* in T cell function is less clear. Earlier reports demonstrated that *Orai3* is upregulated in human effector T cells as a potential mechanism to resist oxidative stress within inflammatory environments (40). A recent study showed that reduced expression of the transcriptional repressor IKAROS causes chronic inflammation through enhanced *Orai3* expression and ARC activity in T cells from rheumatoid arthritis patients (66). Whether native *Orai3* contributes to the miniscule amount of SOCE remaining in *Orai1*<sup>-/-</sup> *Orai2*<sup>-/-</sup> T cells remains unknown (35). Furthermore, whether the composition of native CRAC channels substantially varies between T cell subsets [T helper (Th)1, Th2, Th17, and regulatory T cells (Tregs)] and whether the *Orai* stoichiometry within these subsets in vivo is fixed or dynamic are important questions that remain unanswered.

**CRAC and T cell metabolism.** Patients and mice with SOCE-deficient T cells have largely unaltered thymic T cell development (28). Patients with LoF *Orai1* or *STIM1* display normal frequencies of conventional  $\alpha\beta$  T cell subsets, yet their T cells are severely defective in cytokine and chemokine expression and differentiation into effector subsets and fail to proliferate in response to antigenic stimulation due to the lack of SOCE (3). Furthermore, proliferation of T cells from patients with *Orai1* or *STIM1* LoF mutations is significantly impaired even in the presence of exogenous interleukin 2 (IL-2), which is a potent cytokine that signals through  $\text{Ca}^{2+}$ -independent mechanisms, suggesting that impairment of additional pathways contributes to this proliferative defect (20, 67, 68). Naïve T cells are maintained in a metabolically quiescent state with minimal

biosynthesis, and T cell receptor (TCR) stimulation triggers the rapid uptake of nutrients as T cells prepare to enter the cell cycle and clonally expand (69). This metabolic reprogramming is driven through a key switch from oxidative phosphorylation to aerobic glycolysis, as glucose is the primary carbohydrate source utilized in anabolic metabolism (69). How initiation of SOCE and its downstream signaling effectors, namely the calcineurin-NFAT pathway, contributes to this initial metabolic reprogramming and proliferation of T cells had long been obscure. Utilizing CD4<sup>+</sup> T cell-specific double STIM1/STIM2 knockout (Stim1<sup>fl/fl</sup>Stim2<sup>fl/fl</sup>Cd4<sup>cre</sup>) mice, Feske and coworkers (70) showed that SOCE, through Ca<sup>2+</sup>-dependent activation of NFAT and subsequent upregulation of the transcription factors cellular-Myc (c-Myc), interferon regulatory factor 4 (IRF4), and hypoxia-inducible factor 1 alpha (HIF1 $\alpha$ ), regulates the expression of the glucose transporters GLUT1 and GLUT3, along with key glycolytic and mitochondrial respiration chain enzymes. The transcriptional regulation of these transporters and metabolic enzymes, as well as the expression of the master transcription factors c-Myc, HIF1 $\alpha$ , and IRF4, was mediated through NFAT1 and NFAT2. Ectopic expression of a constitutively active form of NFAT2 or GLUT1 in T cells from Stim1<sup>fl/fl</sup>Stim2<sup>fl/fl</sup>Cd4<sup>cre</sup> mice rescued defects in glucose uptake and c-Myc/HIF1 $\alpha$ /IRF4 expression, while partially restoring in vivo proliferative capacity in response to lymphocytic choriomeningitis virus (LCMV) infection. Conversely, treatment of wild-type T cells with the calcineurin inhibitor FK506 phenocopied the proliferative and metabolic defects of STIM1<sup>-/-</sup> STIM2<sup>-/-</sup> T cells. SOCE and calcineurin were also proposed to post-translationally regulate members of the PI3K-AKT-mTOR (phosphatidylinositol 3-kinase-AKT-mechanistic target of rapamycin) pathway as phosphorylation of AKT, mTOR, and S6 ribosomal protein was significantly impaired in T cells from Stim1<sup>fl/fl</sup>Stim2<sup>fl/fl</sup>Cd4<sup>cre</sup> mice. How Ca<sup>2+</sup> signals through SOCE regulate the PI3K-AKT-mTOR pathway in T cells is currently unclear. These data further highlight the central role of calcineurin in T cell function and the clinical efficacy of calcineurin inhibitors as potent immunosuppressants (71). Interestingly, defects in the proliferation and metabolic reprogramming of STIM1<sup>-/-</sup> STIM2<sup>-/-</sup> T cells can be partially bypassed by IL-2 and IL-7 costimulation, but not by either cytokine alone (70).

**CRAC in specific T cell subsets.** Following maturation in the thymus, T cells commit to various lineages based on expression of the glycoproteins CD4 (helper T cells) and CD8 (cytotoxic T cells) (72). Further differentiation of naive CD4<sup>+</sup> T cells into effector subsets is driven by cytokines and secondary signals that induce activation of lineage-specific transcription factors and gene programs (72). SOCE is critical in driving the differentiation and unique genetic profiles of CD4<sup>+</sup> T cell subsets. In response to immunization or infection with pathogens, the humoral immune response regulates the production of antigen-specific antibodies and long-lived immunological memory. This antibody response is orchestrated through CD4<sup>+</sup> T follicular helper (Tfh) cells that traffic to secondary lymphoid organs to provide cognate help to GC B cells for efficient class-switch recombination and affinity maturation (73). Critically, antigen-specific antibody responses must be counterbalanced by the function of T follicular regulatory (Tfr) cells that dampen the GC response to prevent autoantibody production (73, 74). Vaeth et al. (75) identified a dichotomous role for SOCE in the differentiation of both Tfh and Tfr cells. By studying humoral immune responses to acute and chronic LCMV infection in Stim1<sup>fl/fl</sup>Stim2<sup>fl/fl</sup>Cd4<sup>cre</sup> mice, they showed that SOCE is essential for the expression of the key transcription factors IRF4, basic leucine zipper transcription factor, ATF-like (BATF), and B cell lymphoma 6 (Bcl6) that drive Tfh/Tfr differentiation. Accordingly, LCMV-infected Stim1<sup>fl/fl</sup>Stim2<sup>fl/fl</sup>Cd4<sup>cre</sup> mice display significantly reduced Tfh populations, fail to generate LCMV-specific IgG antibodies, and ultimately succumb to chronic infection. These effects were predominately due to impaired activation of the NFAT2 $\alpha$ A isoform. In agreement with previous work, Stim1<sup>fl/fl</sup>Stim2<sup>fl/fl</sup>Cd4<sup>cre</sup> mice also show

reduced populations of Foxp3<sup>+</sup> central Tregs and even further reductions in differentiation to Foxp3<sup>+</sup> Tfr cells (76). The lack of Tfr populations leaves the GC response unchecked, allowing for expansion of self-reactive Tfh cells, production of autoantibodies from GC B cells, and severe autoimmunity in aging Stim1<sup>fl/fl</sup>Stim2<sup>fl/fl</sup>Cd4<sup>cre</sup> mice (75). These studies argue that the inability to produce antigen-specific antibodies in LoF *Orai1* patients is due to defective Tfh function and differentiation and not to impaired B cell populations.

Although SOCE is dispensable for the development of immune cells, one notable exception is the development of Foxp3<sup>+</sup> Tregs. The role of SOCE in regulating immunological tolerance and preventing autoimmunity has been attributed to defects in development of Foxp3<sup>+</sup> Tregs in the thymus of SOCE-deficient mice (76). It has long been appreciated that the magnitude of SOCE is different between lymphocyte subsets and between naïve and memory T cells (77, 78). Tregs appear to have the largest SOCE response owing to a less prominent *Orai2* expression in these cells (78). However, whether the magnitude of SOCE is related to its unique role in the development of Tregs is unclear. SOCE regulates the complex transcriptional programs that drive peripheral tissue-resident Treg and Tfr differentiation. Using mice lacking STIM1 and STIM2 in mature Foxp3<sup>+</sup> Tregs (Stim1<sup>fl/fl</sup>Stim2<sup>fl/fl</sup>Foxp3<sup>YFPcre</sup>), researchers revealed that SOCE controls the expression of chemokine receptors and integrins required for tissue homing and trafficking, along with multiple metabolic pathways (IL-2 signaling and mTOR) and transcription factors required for tissue-resident Treg differentiation and function (79). Accordingly, tissue-resident Foxp3<sup>+</sup> Treg populations were largely ablated in the bone marrow, liver, and lungs, but not in the blood or secondary lymphoid organs of Stim1<sup>fl/fl</sup>Stim2<sup>fl/fl</sup>Foxp3<sup>YFPcre</sup> mice. Mice with loss of STIM1 and STIM2 in all T cell populations or selectively in Foxp3<sup>+</sup> Tregs develop severe lymphoproliferative and type 2 autoimmune disease driven by robust autoantibody production (79, 80). Interestingly, depletion of B cells substantially reduces autoantibody titers in these mice but is not sufficient to prevent premature death due to systemic multiorgan inflammation, suggesting additional roles of SOCE in regulating Treg function (79).

In addition to altered Treg function, the pathology of a wide variety of autoimmune and inflammatory disorders is driven by another CD4<sup>+</sup> T cell subset, Th17 cells (81). Th17 cells are characterized by the secretion of key proinflammatory cytokines (IL-17A, IL-17F, IL-22) and expression of the master transcriptional regulator retinoic acid-related orphan receptor- $\gamma$  (ROR $\gamma$ ) (81). High-throughput screening for novel CRAC channel inhibitors demonstrated a critical role for *Orai1*-mediated Ca<sup>2+</sup> signals in the differentiation of Th17 cells both in vitro and in vivo (82). Inhibition of SOCE reduced expression of ROR $\gamma$ , ROR $\alpha$ , and IL-23R and protected mice from Th17-mediated experimental autoimmune encephalomyelitis (82, 83). It remains poorly understood why Th17 cells demonstrate increased sensitivity to CRAC channel inhibition compared to other CD4<sup>+</sup> subsets or how SOCE regulates pathogenic Th17 development and metabolism. Kaufmann et al. (84) have identified an unexpected role for SOCE in regulating mitochondrial homeostasis and oxidative phosphorylation of pathogenic Th17 cells. In mice with T cell-specific expression of hyperactive STAT3C, which drives robust expansion of Th17 populations, crossed with Stim1<sup>fl/fl</sup>Cd4<sup>cre</sup> mice to abrogate SOCE specifically in CD4<sup>+</sup> T cells, expression of many subunits of the electron transport chain was significantly downregulated. This coincided with reductions in mitochondrial respiration, alterations in mitochondrial ultrastructure, and protection from Th17 cell-mediated inflammation in vivo. RNA sequencing of Th17 cells from STAT3C Stim1<sup>fl/fl</sup>Cd4<sup>cre</sup> mice showed reversal to a largely nonpathogenic Th17 cell signature. How SOCE controls the expression of many nuclear encoded components of the electron transport chain in Th17 cells is unresolved, but NFAT-dependent mechanisms are likely involved (84). In contrast to classic  $\alpha\beta$  T cells, which are the most abundant T cell lineage in humans and mice, the role of SOCE in the development and effector function of unconventional  $\gamma\delta$  T cells remains unexplored.

## B Cells

The role of SOCE in B cells has been significantly understudied and remains largely enigmatic. A landmark study from Matsumoto et al. (85) established the importance of SOCE in regulating B cell survival and proliferation. Although STIM1 mediated the majority of SOCE in B cells, only the deletion of both STIM proteins in mice (Stim1<sup>fl/fl</sup>Stim2<sup>fl/fl</sup>Mb1<sup>cre</sup>) significantly impaired B cell proliferation and survival. The relatively minor reduction in proliferation of STIM1<sup>-/-</sup> B cells phenocopied that of Orai1<sup>-/-</sup> B cells, which also retain residual SOCE, demonstrating that minute levels of Ca<sup>2+</sup>, likely mediated by remaining STIM2 and Orai2/3, are sufficient to drive antiapoptotic and proliferative gene programs in B cells (59, 60). Paradoxically, Stim1<sup>fl/fl</sup>Stim2<sup>fl/fl</sup>Mb1<sup>cre</sup> mice demonstrated normal antibody titers, GC B cell populations, and antibody affinity maturation to both T cell-dependent and -independent antigens (85). Although STIM1 and STIM2 were dispensable for antigen-specific antibody production, they were required for the efficient activation of NFAT1 and the subsequent production of IL-10 by regulatory B cells. Analogous to other immune cell populations, all B cell subsets in the bone marrow, spleen, and peritoneal cavity of Stim1<sup>fl/fl</sup>Stim2<sup>fl/fl</sup>Mb1<sup>cre</sup> mice were unaltered, suggesting that SOCE is dispensable for B cell development (85). Similarly, B cell populations are unchanged in human patients with LoF mutations in *Orai1* and *STIM1* (28). Interestingly, recent work investigating B cell-specific IP<sub>3</sub>R triple-knockout mice revealed a substantial reduction in conventional B2 and B1 cell populations in peripheral tissues (86). Loss of all three IP<sub>3</sub>Rs also affected acute, but not long-term, T cell-dependent and -independent humoral antibody responses as well as B cell proliferation and survival (86). These results suggest that Ca<sup>2+</sup> signals mediated by IP<sub>3</sub>Rs, but not CRAC channels, are critical for the early positive and negative selection of B cells.

B cell receptor (BCR) stimulation of naïve B cells rapidly upregulates aerobic glycolysis and oxidative phosphorylation to meet the metabolic demands required for efficient B cell differentiation and clonal expansion (87). Berry et al. (88) provided evidence for the critical role of SOCE in regulating B cell survival, cell-cycle entry, and proliferation. They demonstrated that BCR stimulation of STIM1<sup>-/-</sup> STIM2<sup>-/-</sup> B cells results in substantial cell death, as SOCE is critical for the transcription and upregulation of the antiapoptotic protein B cell lymphoma-extra large (Bcl-xL). BCR-mediated Ca<sup>2+</sup> entry activated both NFAT and nuclear factor-kappa B (NF-κB) pathways, ultimately converging on mammalian target of rapamycin complex 1 (mTORC1) activation and induction of c-Myc to drive B cell proliferation (88). The survival and proliferation of STIM1<sup>-/-</sup> STIM2<sup>-/-</sup> B cells can be partially rescued by costimulation with CD40 or Toll-like receptor (TLR) ligands [e.g., lipopolysaccharides (LPS) and cytosine-phosphate-guanine (CpG)] (85, 88). In fact, costimulation with either CD40 or TLR ligands robustly activated the canonical NF-κB and mTORC1 pathways, bypassing the need for BCR-mediated Ca<sup>2+</sup> signaling to promote B cell survival and cell-cycle entry and prevent mitochondrial dysfunction (88, 89). These findings may partially explain the normal antibody responses of Stim1<sup>fl/fl</sup>Stim2<sup>fl/fl</sup>Mb1<sup>cre</sup> mice, where secondary CD40 and cytokine signals from T cells in vivo might compensate for SOCE deficiency in GC B cells. Indeed, GC B cells display attenuated BCR signaling and require robust costimulation with CD40 to induce c-Myc expression and phosphorylation of S6 protein (90). Interestingly, GC B cells also demonstrate unique metabolic demands and preferentially oxidize fatty acids to fuel oxidative phosphorylation (91). The metabolic requirement of SOCE is not restricted to lymphocytes. Analysis of SOCE-deficient fibroblasts and hepatocytes from both humans and mice showed diminished fatty acid oxidation, resulting from impaired activation of master transcription factors peroxisome proliferator-activated receptor-gamma coactivator-1 alpha (PGC-1α) and peroxisome proliferator-activated receptor alpha (PPARα) that facilitate lipid metabolism (92). These data warrant further work to determine whether SOCE regulates similar metabolic programs in GC

B cells or other B cell subsets. Although the work of Berry et al. (88) has reaffirmed the importance of STIM molecules in orchestrating B cell survival and expansion, the precise Orai isoforms that make up CRAC channels in various B cell populations and how the expression of these isoforms is modulated by physiological and pathological stimuli await further investigations.

### Innate Immune Cells

Current evidence suggests a critical role for SOCE in regulating neutrophil nicotinamide adenine dinucleotide phosphate (NADPH) oxidase activation and subsequent reactive oxygen species (ROS) production along with the activation, degranulation, and cytokine secretion of mast cells (93, 94). Using mice with hematopoietic deletion of *Orai1* and/or *Orai2*, researchers recently suggested that Orai1 and Orai2 cooperatively regulate SOCE in mouse neutrophils (95). However, unlike T cells and mast cells, SOCE was decreased in *Orai2*<sup>-/-</sup> neutrophils, although I<sub>CRAC</sub> measurements were not performed on isolated neutrophils from these mice (95). If I<sub>CRAC</sub> indeed turns out to be decreased in *Orai2*<sup>-/-</sup> neutrophils, these results would suggest that Orai2 function varies between innate and adaptive immune cells. Surprisingly, *STIM1*<sup>-/-</sup> *STIM2*<sup>-/-</sup> bone marrow-derived macrophages, dendritic cells, and natural killer cells demonstrate relatively normal effector function and cytolytic activity (96, 97). Whether other Ca<sup>2+</sup>-conducting channels [e.g., transient receptor potential, purinergic receptors, voltage-gated Ca<sup>2+</sup> channels (1)] are more functionally relevant in these innate populations is unclear. Gwack and coworkers (98) identified a Ca<sup>2+</sup>-independent mechanism by which STIM1 may contribute to autoimmune pathology. They characterized fibroblasts and bone marrow-derived macrophages from *STIM1*<sup>-/-</sup> mice along with peripheral blood mononuclear cells from a human patient with a nonsense mutation in *STIM1* (E136X) that ablated STIM1 protein expression (98). Unexpectedly, *STIM1*<sup>-/-</sup>, but not *STIM2*<sup>-/-</sup>, in macrophages increased the expression of genes regulating the type I interferon response. Furthermore, elevated levels of proinflammatory cytokines were found in serum from the *STIM1* E136X patient. This enhanced type I interferon response was absent in *Orai1*<sup>-/-</sup> cells, suggesting that this phenotype is independent of the lack of SOCE. STIM1 was shown to physically interact with the ER-resident adapter protein stimulator of interferon genes (STING) and resting STIM1 retains STING in the ER, reducing its trafficking to the ER-Golgi intermediate compartment, which is required for activation of interferon regulatory factor 3 (IRF3), an interferon-inducing transcription factor. *STIM1*<sup>-/-</sup> cells demonstrated increased resistance to infection with DNA viruses such as herpes simplex virus-1 (HSV-1) and murine  $\gamma$ -herpesvirus. *Stim1*<sup>fl/fl</sup>*Ly2*<sup>cre</sup> mice, which lack STIM1 specifically in myeloid cell populations, were protected from HSV-1-induced death (98). Finally, Demaurex and colleagues (99) reported a critical function of STIM1 in antigen-presenting dendritic cells, whereby STIM1-mediated Ca<sup>2+</sup> signals supported the delivery of endolysosomal enzymes to phagosomes to promote antigen cross-presentation.

Given the dynamic structure of their N and C termini, it is not surprising that STIM proteins possess SOCE-independent functions and likely bind a host of ER and cytosolic proteins, the physiological importance of which is poorly understood. For instance, STIM1 regulates actin stress fiber formation and endothelial permeability in response to agonists independently of SOCE and Orai1 (100). STIM2, but not STIM1, was identified as a novel binding protein for AMPK, regulating its activation through a Ca<sup>2+</sup> mechanism, but not an energy stress-mediated mechanism (101). Furthermore, conflicting reports of STIM proteins directly interacting with IP<sub>3</sub>Rs and regulating their activity necessitate further work to understand potential cross talk between these molecules within the ER network (102, 103). Defining the STIM interactome within various cell types and ER Ca<sup>2+</sup> depletion conditions will be critical to parse out novel Ca<sup>2+</sup>-independent physiological functions for STIM1 and STIM2.

## Platelets

The activation of platelets and thrombus formation at sites of vascular injury critically depend on increases in cytosolic  $\text{Ca}^{2+}$  concentrations through SOCE (104). Earlier studies have established that *Orai1* and *STIM1* are the key regulators of SOCE and procoagulant activity in human and murine platelets with no apparent role for *STIM2* (105–107). Patients with LoF mutations in *Orai1* and *STIM1* show relatively normal numbers of platelets with no increase in bleeding diathesis. However, intermittent periods of thrombocytopenia occur owing to autoantibodies against platelet glycoproteins (28). Conversely, patients with gain-of-function (GoF) mutations in *Orai1* or *STIM1* generating constitutively active CRAC channels manifest with a host of platelet defects and the development of York platelet and Stormorken syndromes (108–111). Both disorders are characterized by thrombocytopenia, increased bleeding, and skeletal myopathy and are caused by the same activating R304W mutation located in the *STIM1* C terminus (28). York platelet syndrome is also caused by the additional I115F mutation located within the EF2 motif of *STIM1* (108). Platelets from these patients are preactivated with plasma membrane phosphatidylserine exposure, impaired ATP secretion, and altered ultrastructure (108–110). Heterologous expression of the *STIM1*-R304W mutant results in preclustered *STIM1* puncta, constitutive activation of  $\text{I}_{\text{CRAC}}$ , and enhanced SOCE compared to wild-type *STIM1* (111, 112). Romanin and colleagues (112) have shown that the R304W mutation promotes *STIM1* C terminus unfolding by increasing the homomerization and helical elongation of its coiled-coil 1 domain (CC1), thus exposing the *STIM1* SOAR/CAD, which is normally shielded by CC1 under store replete conditions. Interestingly, patients with constitutively active CRAC channel activity due to mutations in the *STIM1* EF-hand (e.g., D84G) that lead to preclustering of *STIM1* manifest with nonsyndromic tubular-aggregate myopathy but no obvious platelet defects or bleeding disorders (113). The more severe phenotype of the *STIM1*-R304W mutation may result from the lack of fast  $\text{Ca}^{2+}$ -dependent inactivation of CRAC channels, which is unaffected in the *STIM1* EF-hand mutants (111). Nevertheless, heterozygous *Stim1*<sup>Sax</sup> mice with the *STIM1* D84G mutation found in patients, present with thrombocytopenia, increased bleeding times and preactivated platelets (114). The discrepancy in bleeding diathesis between patients harboring this mutation and *Stim1*<sup>Sax</sup> mice is currently unclear. Recently, two new *STIM1* GoF mouse models have been developed by multiple groups and carry the human equivalent of the York platelet I115F mutation or the Stormorken R304W mutation (115–117). Homozygosity for the R304W mutation is embryonic lethal, while the outcome of homozygous I115F mice was not reported. Thrombocytopenia, prolonged bleeding times, and impaired platelet function were observed in both heterozygous R304W and I115F *STIM1* GoF mice (115–117).

## ECTODERMAL-DERIVED AND OTHER SECRETORY TISSUES

### Enamel Mineralization

In patients afflicted with LoF mutations in *Orai1* and *STIM1*, some of the most frequently reported symptoms are severe defects in dental enamel formation (118). The process of enamel formation, termed amelogenesis, is driven by polarized ameloblast cells, which are derived from the ectodermal epithelium (119, 120). Amelogenesis is initiated in a secretory stage whereby ameloblasts apically secrete a multitude of enamel matrix proteins to structurally support enamel crystal growth (119, 120). During the final maturation or mineralization stage, ameloblasts differentiate into a ruffled phenotype, transporting  $\text{Ca}^{2+}$  from the bloodstream to be deposited extracellularly in the enamel matrix to drive de novo hydroxyapatite crystal formation (118). Supporting a transcytosis model where  $\text{Ca}^{2+}$  is transported across ameloblasts through the ER network, early genome-wide

transcript profiling studies identified upregulation of *STIM1* and *STIM2* in developing rat enamel tissue (121). All five components of the SOCE machinery and IP<sub>3</sub>Rs are expressed in the maturation stage of enamel tissue, and Ca<sup>2+</sup> entry is potently blocked by the SOCE inhibitor Synta-66, suggesting functional CRAC channels in enamel cells (122). Lacruz and colleagues (123) generated Stim1<sup>fl/fl</sup>Stim2<sup>fl/fl</sup> K14<sup>cre</sup> mice to ablate SOCE in keratin-expressing ectodermally derived tissues such as dental enamel. The enamel of Stim1<sup>fl/fl</sup>Stim2<sup>fl/fl</sup> K14<sup>cre</sup> mice was severely hypomineralized, reduced in thickness and volume, and mechanically weak compared to enamel from wild-type incisors. Critically, the key Na<sup>+</sup>/Ca<sup>2+</sup>/K<sup>+</sup> exchanger NCKX4, which mediates Ca<sup>2+</sup> extrusion out of the apical end of ameloblasts, was mislocalized, likely contributing to the mineralization defect in these mice. Ameloblasts from Stim1<sup>fl/fl</sup>Stim2<sup>fl/fl</sup> K14<sup>cre</sup> mice have altered morphology and defects in formation of a ruffled border, along with high proportions of mislocalized mitochondria with damaged cristae formation and elevated levels of ROS. Alterations in the glutathione system in STIM1<sup>-/-</sup> STIM2<sup>-/-</sup> ameloblasts impairs the S-glutathionylation of actin, likely contributing to impaired formation of the ruffled border. This phenotype appears largely driven by STIM1-mediated SOCE, as similar work showed that enamel defects are found in Stim1<sup>fl/fl</sup> K14<sup>cre</sup> and Stim1<sup>fl/fl</sup>Stim2<sup>fl/fl</sup> K14<sup>cre</sup> mice, but not Stim2<sup>fl/fl</sup> K14<sup>cre</sup> mice (124). In Orai1<sup>fl/fl</sup> K14<sup>cre</sup> and global Orai2<sup>-/-</sup> mice, SOCE was reduced by ~50% in Orai1<sup>-/-</sup> enamel organ cells, whereas SOCE increased in Orai2<sup>-/-</sup> enamel organ cells (37), consistent with a function for Orai2 as a negative regulator of CRAC channels in enamel cells. Enamel defects were observed in Orai1<sup>fl/fl</sup> K14<sup>cre</sup> mice, but not Orai2<sup>-/-</sup> mice, suggesting that increased SOCE does not substantially alter ameloblast function and enamel formation (37). The mouse enamel cell line LS8 with stable short hairpin RNA (shRNA) knockdown for each Orai isoform demonstrated a substantial reduction in SOCE with Orai1 knockdown, and an increase with either Orai2 or Orai3 knockdown, with a less dramatic increase in SOCE with Orai3 knockdown (37). Thus, all members of the Orai trio contribute to the CRAC channel in enamel cells, with Orai2 and Orai3 acting as robust and moderate negative regulators of CRAC channel activity, respectively, in agreement with studies in HEK293 cells (27, 36).

### Other Secretory Tissues

Studies on global and tissue-specific STIM1<sup>-/-</sup> and Orai1<sup>-/-</sup> mice revealed crucial roles for SOCE in sweat, tears, milk, and gastric fluid secretion. Patients with LoF in *Orai1* and *STIM1* display ectodermal dysplasia characterized by anhidrosis (28), the inability to sweat. Increases in intracellular Ca<sup>2+</sup> concentrations within eccrine sweat glands result in the opening of Ca<sup>2+</sup>-activated chloride channels (125), which provide the driving force for water release and sweat production. Concepcion et al. (126) studied sweat glands from Stim1<sup>fl/fl</sup>Stim2<sup>fl/fl</sup> K14<sup>cre</sup> and Orai1<sup>fl/fl</sup> K14<sup>cre</sup> mice along with skin biopsies from patients with LoF mutations in *Orai1* and *STIM1*. Patient samples demonstrated the presence of eccrine sweat glands with relatively normal morphology, suggesting that anhidrosis in these patients is not due to defects in sweat gland development. In response to cholinergic stimulation, however, the footpads of Stim1<sup>fl/fl</sup>Stim2<sup>fl/fl</sup> K14<sup>cre</sup> and Orai1<sup>fl/fl</sup> K14<sup>cre</sup> mice showed minimal sweat secretion. Similarly, Cl<sup>-</sup> secretion of isolated sweat glands from Orai1<sup>fl/fl</sup> K14<sup>cre</sup> mice and in the human sweat gland cell line NCL-SG3 subjected to Orai1 or STIM1 knockdown was significantly reduced in response to acetylcholine stimulation. Ca<sup>2+</sup>-activated chloride channel-mediated Cl<sup>-</sup> currents activated by acetylcholine were mediated by the TMEM16A protein and were largely attenuated upon Orai1 knockdown (126).

Work by Putney and colleagues (127) showed that lacrimal gland cells isolated from global Orai1<sup>-/-</sup> mice lack SOCE. Although lacrimal glands from these Orai1<sup>-/-</sup> mice showed

normal morphology,  $\text{Ca}^{2+}$ -dependent exocytotic secretion of peroxidase was abrogated and tear production was severely reduced in response to injection with the muscarinic receptor agonist pilocarpine (127). The same group showed that, although global female *Orai1*<sup>-/-</sup> mice were fertile, their produced pups failed to survive and thrive unless they were fostered by a wild-type surrogate mother. Female *Orai1*<sup>-/-</sup> mice present with a reduction of  $\text{Ca}^{2+}$  transport into milk by approximately 50% and altered milk ejection from mammary glands. The oxytocin-mediated pulsatile contractions of the alveolar units of mammary glands from *Orai1*<sup>-/-</sup> mice were infrequent and poorly coordinated compared to those of control mice (128). The oxytocin-activated cytosolic  $\text{Ca}^{2+}$  oscillations in mammary myoepithelial cells from *Orai1*<sup>-/-</sup> mice were also severely reduced in number, amplitude, and frequency, arguing for a critical role of these *Orai1*-mediated repetitive  $\text{Ca}^{2+}$  oscillations in milk ejection and pup survival. This study revealed a dual role for *Orai1* in concentrating milk with  $\text{Ca}^{2+}$  and in contractile signaling of mammary myoepithelial cells required for milk ejection. Quite intriguingly, the same group revealed that male *Orai1*<sup>-/-</sup> mice were sterile due to defects in spermatogenesis, with defects in spermatid maturation and degeneration of the seminiferous tubules within the testes (129). Interestingly, activation of the G protein-coupled tastant receptor in mouse spermatids couples to the G protein gustducin, PLC, and  $\text{Ca}^{2+}$  signaling and mice with deletions in these taste genes present with defects in spermatogenesis (130). While the precise mechanisms by which SOCE controls spermatogenesis await further investigations, *Orai1* might mediate the  $\text{Ca}^{2+}$  entry pathway that is activated by tastant receptors and required for spermatid development (129).

Ahuja et al. (131) generated mice with tamoxifen-inducible tissue-specific deletion of *Orai1* in pancreatic acini using the *ErT<sub>Cre</sub>* line, which is driven by the elastase promoter. About 60–70% of adult *Orai1*<sup>fl/fl</sup>*ErT<sub>Cre</sub>* mice die within three weeks of tamoxifen treatment. Although *Orai1*<sup>fl/fl</sup>*ErT<sub>Cre</sub>* mice had largely preserved gut innate immunity, they showed reduced pancreatic levels of cathelicidin-related antimicrobial peptide with enhanced bacterial outgrowth in intestines, systemic infection, and dysbiosis (131). Survival of *Orai1*<sup>fl/fl</sup>*ErT<sub>Cre</sub>* mice was rescued by strategies that curbed bacterial outgrowth, such as antibiotics or a purified liquid diet, but not with digestive enzyme supplementation, suggesting a crucial role of *Orai1*-mediated  $\text{Ca}^{2+}$  entry in antimicrobial secretions by pancreatic acini that prevent disruption of the gut microbiome (131).

## **SKELLETAL, CARDIAC, AND SMOOTH MUSCLE**

### **Skeletal Muscle**

One tissue where both the short-term sarcoplasmic reticulum (SR) store refilling and long-term  $\text{Ca}^{2+}$ -dependent signaling functions of SOCE are readily apparent is skeletal muscle. SOCE prevents skeletal muscle fatigue during periods of prolonged, high-frequency contraction and is crucial to muscle fiber development (132, 133). Although SOCE in nonexcitable cells is a slow process that takes seconds to develop and minutes to be maximal, in skeletal muscle, store depletion leads to a more rapid SOCE activation (<1 s), likely due to the sizeable portion of STIM1 that is permanently prelocalized with *Orai1* under store replete conditions within the SR-transverse tubule junctions (132). This precoupling is mediated by a long splice variant of STIM1 that contains 106 additional amino acids (called STIM1L) and binds to actin, allowing constitutive interactions with *Orai1* even when stores are full (55). Most studies have focused on STIM1 and *Orai1*, which are highly expressed in both myotubes and adult muscle fibers. Although myotubes express abundant mRNA for STIM2, *Orai2*, and *Orai3*, the contribution of these isoforms to fine-tuning skeletal muscle SOCE and contractile activity or to long-term differentiation and growth through  $\text{Ca}^{2+}$ -dependent transcription remains unknown. Patients with both LoF and GoF mutations in *STIM1*

and *Orai1* display a diverse range of muscle disorders, including atrophy, hypotonia, and tubular aggregate myopathy (28).

Patients bearing the archetypical R91W homozygous LoF mutation in *Orai1* present with enhanced numbers of type I muscle fibers and atrophic type II fibers (15). Most global *STIM1*<sup>-/-</sup> and *Orai1*<sup>-/-</sup> mice die, but those that survive on mixed backgrounds are smaller in size and exhibit reduced muscle mass, indicating *Orai1*'s important role in long-term skeletal muscle fiber differentiation, growth, and development (134). Several Ca<sup>2+</sup>-dependent transcription factors were proposed to mediate the effects of SOCE on skeletal muscle development, including NFAT, AKT, mitogen-activated protein kinase, and extracellular signal-regulated kinase 1/2 (132). Several patients with GoF mutations in *STIM1* and *Orai1*, causing constitutively active SOCE, have been identified and were associated with a collection of syndromes affecting skeletal muscle function, including tubular aggregate myopathy. They also exhibited other pathologies affecting muscle and other organ systems such as Stormorken and York platelet syndromes, which were briefly discussed above and in detail elsewhere (132). Altered SOCE activity was also proposed to contribute to the exacerbation of other skeletal muscle pathologies with different etiologies such as Duchenne muscular dystrophy in patients and in the *mdx* mice model, malignant hyperthermia caused by mutations in type I ryanodine receptor, and age-related skeletal muscle decline (132).

### Cardiac and Smooth Muscle

While healthy acutely isolated cardiomyocytes and smooth muscle cells express *STIM1* proteins, the expression of *Orai1* is either low (vascular smooth muscle) (135–137) or undetectable (ventricular cardiomyocytes) (138) with undetectable SOCE activity and I<sub>CRAC</sub> in both cell types (137, 138). In rat ventricular myocytes, *STIM1* enhances SR Ca<sup>2+</sup> content by binding to phospholamban (138), suggesting the existence of SOCE-independent functions of *STIM1*, as reported in macrophages and endothelial cells (98, 100). Several groups showed a homeostatic role of cardiomyocyte *STIM1* in the adult heart, but whether or not this function of *STIM1* is mediated through *Orai* channels remains unclear. Inducible cardiomyocyte-specific *STIM1* knockdown mice were prone to malignant ventricular arrhythmias and death (139). Noninducible cardiomyocyte-specific *STIM1* knockdown mice showed increased ER stress and mitochondrial dysfunction, and they displayed cardiac inflammation, fibrosis, and decline in cardiac function with a subsequent onset of left ventricular dilatation by 9 months of age (140). The reduction of cardiac *STIM1* expression by siRNA *in vivo* led to heart failure driven by abrogated AKT/mTORC2 signaling and enhanced activity of glycogen synthase kinase-3 beta (GSK-3β), an antihypertrophic and proapoptotic kinase (141). The role of *STIM1* in the cellular homeostasis of quiescent healthy smooth muscle remains largely unknown. Vascular and intestinal smooth muscle tissues from smooth muscle-specific *STIM1* knockout (*Stim1*<sup>fl/fl</sup>*SM22α*<sup>cre</sup>) mice were distended and thin, suggesting altered development (142). Mesenteric arteries and aortas from these mice had reduced α1-adrenergic-dependent contraction by ~25–50% with preserved thromboxane- and depolarization-induced contraction (142–144). Finally, the use of a peptide that inhibits *STIM1*–*Orai1* interactions suggested a critical role of CRAC channels in the pacemaker activity by the interstitial cells of Cajal within the gastrointestinal tract (145).

Unlike the situation of the healthy cardiovascular system, the expression of *STIM1* and *Orai1* and the magnitude of I<sub>CRAC</sub> and NFAT activity are greatly enhanced in cardiomyocytes and smooth muscle cells under conditions of pathological remodeling of the heart and vessels (146). Genetic abrogation of *STIM1* or *Orai1* expression *in vivo* in hearts and vessels protected rats from pressure overload-induced cardiac hypertrophy and neointima formation, respectively (137, 147, 148). Consistent with these findings, transgenic mice overexpressing *STIM1* die suddenly at 6 weeks

of age, and mice that survive past 12 weeks of age develop hypertrophy and heart failure and show enhanced NFAT and CaMKII activity in their cardiomyocytes (149). STIM1, Orai1, and SOCE are also upregulated in vascular smooth muscle from hypertensive rats (150), and their upregulation is also a hallmark of airway smooth muscle remodeling in mouse models of asthma (151). As mentioned earlier, Orai3 is also a component of store-independent ARC channels composed of Orai1/Orai3 heteromers (38, 63–65). Evolutionarily speaking, Orai proteins appeared before STIM, suggesting that this store-independent gating mechanism of Orai channels predates SOCE (152). Intriguingly, specific deletion of cardiomyocyte Orai3 in mice caused mitochondrial dysfunction with enhanced mitochondrial fission and increased activity of calcineurin, with mice showing impaired left ventricular contractility with progression to dilated cardiomyopathy and heart failure (153), suggesting a homeostatic role for Orai3 in cardiac function. In contrast, Orai3 expression and ARC currents were increased in hypertrophied cardiomyocytes (154) and in neonatal carotid artery smooth muscle from mice subjected to balloon angioplasty (155, 156), and the knockdown of Orai3 *in vivo* in injured carotids inhibited neointima formation (155). These results suggest a complex role of Orai3 in both cardiovascular physiology and pathophysiology, but additional studies are needed to determine the relative contributions of Orai3 to  $I_{CRAC}$ - and  $I_{ARC}$ -mediated signaling in hearts and vessels.

## NERVOUS SYSTEM

### Neurons

Dysregulation of neuronal  $Ca^{2+}$  homeostasis is linked to a variety of neurodegenerative disorders (8). Although voltage-gated  $Ca^{2+}$  channels and ionotropic neurotransmitter receptors are classically ascribed as the primary channels regulating synaptic transmission, neurotransmitter release, and dendritic spine formation, a growing body of literature has implicated STIM and Orai proteins in the function of neurons from various regions of the brain and spinal cord (157). Nevertheless, the function of CRAC channels in the brain remains highly contentious, with several conflicting reports on the expression and contribution of specific STIM and Orai isoforms to  $Ca^{2+}$  signals in various neuron subsets. These issues are compounded by the vast reliance on single-wavelength  $Ca^{2+}$  dyes for  $Ca^{2+}$  measurements in neurons and the inherent difficulties in reliably dissecting and measuring  $I_{CRAC}$  in primary neurons.

Berna-Erro et al. (48) reported that STIM2 and Orai2 messenger RNA are predominantly expressed in mouse brain. The same group showed that SOCE in cortical and hippocampal neurons from STIM2<sup>-/-</sup> mice is significantly inhibited, whereas SOCE is largely unaffected in both STIM1- and Orai1-deficient neurons (48). Global STIM2<sup>-/-</sup> mice showed protection from ischemic stroke, reduced neuronal  $Ca^{2+}$  overload, and apoptosis (48). Similarly, Sun et al. (158) reported a critical role of STIM2-mediated SOCE in the maintenance of mushroom postsynaptic spines through constitutive CaMKII activation. SOCE was substantially reduced in cortical neurons, but not in astrocytes or microglia, from Orai2<sup>-/-</sup> mice. Like STIM2<sup>-/-</sup> mice, Orai2<sup>-/-</sup> mice were largely protected from neuronal damage after cerebral ischemia, presumably by preventing ischemia-induced  $Ca^{2+}$  accumulation and hypoxia-mediated neuronal apoptosis (159). Of note, Orai2<sup>-/-</sup> mice display no defects in cognitive function, but global loss of STIM2 results in more robust cognitive impairment (48, 159). Studies by Hartmann et al. (160) on mice lacking STIM1 in cerebellar Purkinje neurons showed a requirement for STIM1 in IP<sub>3</sub>-mediated  $Ca^{2+}$  release from ER stores, metabotropic glutamate receptor (mGluR)-mediated synaptic transmission, and motor coordination. A subsequent report by the same group showed that Orai2 mRNA is most expressed (compared to Orai1 and Orai3 mRNA) and is required for IP<sub>3</sub>R-mediated  $Ca^{2+}$  release from internal stores of hippocampal CA1 pyramidal neurons in response to mGluR stimulation

and suggested that store refilling in these neurons is mediated by Orai2 (161). Thus, while it appears that SOCE in neurons might be mediated through a privileged interaction between Orai2 and STIM2, studies discussed above did not offer direct measurements of ER  $\text{Ca}^{2+}$  content or that of  $I_{\text{CRAC}}$  in neurons. As such, the exact contribution of Orai2 to the makeup of CRAC channels in neurons warrants further investigations.

A thorough new study by Prakriya and colleagues (162) documented Orai1 protein expression in mouse hippocampus. This study utilized three neuron-specific Orai1 knockout mouse models, combined with Orai1 rescue and the use of CRAC channel pharmacological blockers to show that Orai1 mediates SOCE, ER refilling, and the amplification of neurotransmitter-induced  $\text{Ca}^{2+}$  signals in dendritic spines of hippocampal neurons (162). Stimulation of N-methyl-D-aspartate (NMDA) glutamate receptors and subsequent Orai1-mediated  $\text{Ca}^{2+}$  signals was critical for long-term potentiation of CA1 neurons, CaMKII activation, insertion of new glutamate receptor 1 (Glu1A) subunits of  $\alpha$ -amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptors into postsynaptic densities, spine morphogenesis, and maintenance of synaptic plasticity. Critically, the loss of Orai1 specifically in excitatory neurons using Orai1<sup>fl/fl</sup>CaMKIIa<sup>cre</sup> mice was sufficient to cause substantial impairment of spatial working and associative memory (162). Notably, Orai1 knockout mice showed no deficits in general locomotor and sensorimotor activity. These data agree with those from other recent studies suggesting that Orai1 contributes to nociceptive and learning behaviors (163, 164). Although studies reporting that either one STIM/Orai duo or another mediates neuronal SOCE might appear inconsistent, CRAC channels are likely heteromers of two or three Orai isoforms (27, 36), and it is conceivable that the molecular composition of neuronal SOCE would involve dynamic choreographies between all five STIM/Orai isoforms, as recently shown in nonexcitable cells (45). For instance, double STIM1/STIM2 forebrain-deficient mice showed significant defects in spatial learning and memory with enhanced long-term potentiation of CA3-CA1 hippocampal synapses, whereas single STIM forebrain-deficient mice showed only mild (STIM1) or no (STIM2) defects (165), arguing that both STIM proteins are important for neuronal function. One interesting observation is the implicit requirement of STIM/Orai for the refilling of ER stores in neurons, as they are largely dispensable for long-term ER refilling in nonexcitable cells (27). The picture is complicated further by the SOCE-independent functions of STIM1 in neurons. Indeed, Garcia-Alvarez et al. (166) reported that STIM2 is required for cAMP/PKA-mediated phosphorylation and trafficking of the AMPA receptor subunit GluA1 to the cell surface of hippocampal excitatory neurons in a SOCE-independent manner. Dittmer et al. (167) reported that glutamate-mediated STIM1 aggregation inhibits voltage-gated  $\text{Ca}^{2+}$  channels and NFATc3 nuclear translocation in hippocampal neurons. Clearly, additional experiments are needed with combinations of STIM- and Orai-deficient neurons to determine the contribution of each isoform to amplifying neurotransmitter-induced  $\text{Ca}^{2+}$  signals, synaptic plasticity, memory formation, and motor coordination.

## Astrocytes

Although electrically nonexcitable, astrocytes display dynamic  $\text{Ca}^{2+}$  oscillatory behavior that regulates the release of gliotransmitters (e.g., ATP and glutamate), which modulate the function of surrounding glia and neurons (168). Early work by Motiani et al. (43) showed that SOCE is mediated by Orai1 and STIM1 in primary human astrocytes and a variety of glioblastoma cell lines. Two recent studies confirmed that SOCE in primary cultured murine astrocytes is mostly mediated by Orai1 and STIM1 (169, 170). Similarly, SOCE in microglia is predominately regulated by Orai1 and STIM1, with minor contributions from STIM2 (171, 172). Toth et al. (173) generated astrocyte-specific Orai1 knockout and brain-specific STIM1 knockout mice and showed

that SOCE activated by metabotropic, purinergic, and protease-activated receptors (PARs) in hippocampal astrocytes is mediated by STIM1 and Orai1 and is critical for astrocyte-mediated release of gliotransmitters, such as ATP. Critically, PAR-dependent activation of Orai1 in astrocytes increased inhibitory postsynaptic currents of CA1 pyramidal neurons (173).

## SUMMARY AND FUTURE DIRECTIONS

Recent studies have established CRAC channels as central players in the regulation of  $\text{Ca}^{2+}$  signaling and physiological functions in many organ systems and have shown that either GoF or LoF mutations in STIM/Orai proteins are associated with disease. The expression of all five isoforms of STIM and Orai is ubiquitous, and relative expression of these isoforms in different tissues is incredibly diverse and depends on the specific cell type and its differentiation state. Although Orai1 and STIM1 are clearly the major components of CRAC channels, STIM2, Orai2, and Orai3 are emerging as important regulators of SOCE and cellular function. It should be noted that most protocols used by investigators to interrogate SOCE or CRAC channel activity rely on maximal store depletion and often reveal clear roles for Orai1 and STIM1. However, these protocols are not always suitable for detecting the more subtle regulatory functions of other STIM/Orai isoforms, whose functions become apparent under relatively low to moderate physiological concentrations of agonist. CRISPR/Cas9 knockout in cell lines and transgenic and tissue-specific knockout mouse models have revealed unexpected roles for all Orai isoforms and suggested that they function as heteromeric channels under native conditions. Yet, the exact oligomeric states of CRAC channels remain unclear. CRAC channel stoichiometries are likely driven by diverse mechanisms, including the relative protein abundance of each STIM and Orai isoform in a specific cell. Future studies will likely reveal that the Orai subunit composition of CRAC channels varies between different tissues and differentiation/activation states, and this knowledge will be critical in the specific targeting of CRAC channels by small-molecule drugs for the purpose of disease therapy. Novel mouse models with a specifically altered function of either one STIM or one Orai isoform or combinations of STIM/Orai isoforms will likely shed more light on the composition and physiological function of CRAC channels in different tissues and different cell types. Knockout studies in mice and cells have their shortcomings. For instance, based on previous studies it seems highly likely that if two Orai isoforms form native heterohexameric CRAC channels in a specific cell type and one of them is deleted, the remaining Orai isoform would continue to be functional, albeit as a homohexamer. Mouse knock-in models with different Orai isoforms tagged with fluorescent proteins combined with total internal reflection fluorescence (TIRF) and superresolution imaging in primary cells might overcome this challenge and help inform the native CRAC channel composition. The advancement in *in vivo*  $\text{Ca}^{2+}$  imaging in whole animals using tissue-specific genetically encoded indicators targeted to subcellular compartments combined with physiological and behavioral studies will enhance our knowledge of the signaling mechanisms of native CRAC channels, their physiological function, and their contribution to disease.

## DISCLOSURE STATEMENT

The authors are not aware of any affiliations, memberships, funding, or financial holdings that might be perceived as affecting the objectivity of this review.

## ACKNOWLEDGMENTS

Research in the authors' laboratory is supported by NIH/NHLBI grant R35-HL150778 to M.T.

## LITERATURE CITED

1. Trebak M, Kinet JP. 2019. Calcium signalling in T cells. *Nat. Rev. Immunol.* 19:154–69
2. Clapham DE. 2007. Calcium signaling. *Cell* 131:1047–58
3. Feske S, Skolnik EY, Prakriya M. 2012. Ion channels and transporters in lymphocyte function and immunity. *Nat. Rev. Immunol.* 12:532–47
4. Hogan PG, Rao A. 2015. Store-operated calcium entry: mechanisms and modulation. *Biochem. Biophys. Res. Commun.* 460:40–49
5. Prakriya M, Lewis RS. 2015. Store-operated calcium channels. *Physiol. Rev.* 95:1383–436
6. Shaw PJ, Feske S. 2012. Regulation of lymphocyte function by ORAI and STIM proteins in infection and autoimmunity. *J. Physiol.* 590:4157–67
7. Arruda AP, Hotamisligil GS. 2015. Calcium homeostasis and organelle function in the pathogenesis of obesity and diabetes. *Cell Metab.* 22:381–97
8. Zhang I, Hu H. 2020. Store-operated calcium channels in physiological and pathological states of the nervous system. *Front. Cell. Neurosci.* 14:600758
9. Putney JW Jr. 1986. A model for receptor-regulated calcium entry. *Cell Calcium* 7:1–12
10. Trebak M, Putney JW Jr. 2017. ORAI calcium channels. *Physiology* 32:332–42
11. Park CY, Hoover PJ, Mullins FM, Bachhawat P, Covington ED, et al. 2009. STIM1 clusters and activates CRAC channels via direct binding of a cytosolic domain to Orai1. *Cell* 136:876–90
12. Yuan JP, Zeng W, Dorwart MR, Choi YJ, Worley PF, Muallem S. 2009. SOAR and the polybasic STIM1 domains gate and regulate Orai channels. *Nat. Cell Biol.* 11:337–43
13. Hoth M, Penner R. 1992. Depletion of intracellular calcium stores activates a calcium current in mast cells. *Nature* 355:353–56
14. Lewis RS, Cahalan MD. 1989. Mitogen-induced oscillations of cytosolic  $Ca^{2+}$  and transmembrane  $Ca^{2+}$  current in human leukemic T cells. *Cell Regul.* 1:99–112
15. McCarl CA, Picard C, Khalil S, Kawasaki T, Rother J, et al. 2009. ORAI1 deficiency and lack of store-operated  $Ca^{2+}$  entry cause immunodeficiency, myopathy, and ectodermal dysplasia. *J. Allergy Clin. Immunol.* 124:1311–18.e7
16. Lian J, Cuk M, Kahlfuss S, Kozhaya L, Vaeth M, et al. 2018. *ORAI1* mutations abolishing store-operated  $Ca^{2+}$  entry cause anhidrotic ectodermal dysplasia with immunodeficiency. *J. Allergy Clin. Immunol.* 142:1297–310.e11
17. Feske S, Gwack Y, Prakriya M, Srikanth S, Puppel SH, et al. 2006. A mutation in Orai1 causes immune deficiency by abrogating CRAC channel function. *Nature* 441:179–85
18. Picard C, McCarl CA, Papolos A, Khalil S, Lüthy K, et al. 2009. *STIM1* mutation associated with a syndrome of immunodeficiency and autoimmunity. *N. Engl. J. Med.* 360:1971–80
19. Vaeth M, Feske S. 2018. Ion channelopathies of the immune system. *Curr. Opin. Immunol.* 52:39–50
20. Feske S, Müller JM, Graf D, Kroczek RA, Dräger R, et al. 1996. Severe combined immunodeficiency due to defective binding of the nuclear factor of activated T cells in T lymphocytes of two male siblings. *Eur. J. Immunol.* 26:2119–26
21. Feske S, Giltman J, Dolmetsch R, Staudt LM, Rao A. 2001. Gene regulation mediated by calcium signals in T lymphocytes. *Nat. Immunol.* 2:316–24
22. Le Deist F, Hivroz C, Partiseti M, Thomas C, Buc HA, et al. 1995. A primary T-cell immunodeficiency associated with defective transmembrane calcium influx. *Blood* 85:1053–62
23. Liou J, Kim ML, Heo WD, Jones JT, Myers JW, et al. 2005. STIM is a  $Ca^{2+}$  sensor essential for  $Ca^{2+}$ -store-depletion-triggered  $Ca^{2+}$  influx. *Curr. Biol.* 15:1235–41
24. Roos J, DiGregorio PJ, Yeromin AV, Ohlsen K, Lioudyno M, et al. 2005. STIM1, an essential and conserved component of store-operated  $Ca^{2+}$  channel function. *J. Cell Biol.* 169:435–45
25. Vig M, Peinelt C, Beck A, Koomoa DL, Rabah D, et al. 2006. CRACM1 is a plasma membrane protein essential for store-operated  $Ca^{2+}$  entry. *Science* 312:1220–23
26. Zhang SL, Yeromin AV, Zhang XH, Yu Y, Safrina O, et al. 2006. Genome-wide RNAi screen of  $Ca^{2+}$  influx identifies genes that regulate  $Ca^{2+}$  release-activated  $Ca^{2+}$  channel activity. *PNAS* 103:9357–62
27. Yoast RE, Emrich SM, Trebak M. 2020. The anatomy of native CRAC channel(s). *Curr. Opin. Physiol.* 17:89–95

28. Lacruz RS, Feske S. 2015. Diseases caused by mutations in *ORAI1* and *STIM1*. *Ann. N. Y. Acad. Sci.* 1356:45–79
29. Cai X. 2007. Molecular evolution and structural analysis of the Ca<sup>2+</sup> release-activated Ca<sup>2+</sup> channel subunit, Orai. *J. Mol. Biol.* 368:1284–91
30. Lis A, Peinelt C, Beck A, Parvez S, Monteilh-Zoller M, et al. 2007. CRACM1, CRACM2, and CRACM3 are store-operated Ca<sup>2+</sup> channels with distinct functional properties. *Curr. Biol.* 17:794–800
31. Mercer JC, Dehaven WI, Smyth JT, Wedel B, Boyles RR, et al. 2006. Large store-operated calcium selective currents due to co-expression of Orai1 or Orai2 with the intracellular calcium sensor, Stim1. *J. Biol. Chem.* 281:24979–90
32. Ay AS, Benzerdjeb N, Sevestre H, Ahidouch A, Ouadid-Ahidouch H. 2013. Orai3 constitutes a native store-operated calcium entry that regulates non small cell lung adenocarcinoma cell proliferation. *PLoS ONE* 8:e72889
33. Motiani RK, Abdullaev IF, Trebak M. 2010. A novel native store-operated calcium channel encoded by Orai3: selective requirement of Orai3 versus Orai1 in estrogen receptor-positive versus estrogen receptor-negative breast cancer cells. *J. Biol. Chem.* 285:19173–83
34. Tsvilovskyy V, Solís-López A, Schumacher D, Medert R, Roers A, et al. 2018. Deletion of Orai2 augments endogenous CRAC currents and degranulation in mast cells leading to enhanced anaphylaxis. *Cell Calcium* 71:24–33
35. Vaeth M, Yang J, Yamashita M, Zee I, Eckstein M, et al. 2017. ORAI2 modulates store-operated calcium entry and T cell-mediated immunity. *Nat. Commun.* 8:14714
36. Yoast RE, Emrich SM, Zhang X, Xin P, Johnson MT, et al. 2020. The native ORAI channel trio underlies the diversity of Ca<sup>2+</sup> signaling events. *Nat. Commun.* 11:2444
37. Eckstein M, Vaeth M, Aulestia FJ, Costiniti V, Kassam SN, et al. 2019. Differential regulation of Ca<sup>2+</sup> influx by ORAI channels mediates enamel mineralization. *Sci. Signal.* 12:eaav4663
38. Zhang X, Gonzalez-Cobos JC, Schindl R, Muik M, Ruhle B, et al. 2013. Mechanisms of STIM1 activation of store-independent leukotriene C4-regulated Ca<sup>2+</sup> channels. *Mol. Cell. Biol.* 33:3715–23
39. Ben-Kasus Nissim T, Zhang X, Elazar A, Roy S, Stolwijk JA, et al. 2017. Mitochondria control store-operated Ca<sup>2+</sup> entry through Na<sup>+</sup> and redox signals. *EMBO J.* 36:797–815
40. Bogeski I, Kummerow C, Al-Ansary D, Schwarz EC, Koehler R, et al. 2010. Differential redox regulation of ORAI ion channels: a mechanism to tune cellular calcium signaling. *Sci. Signal.* 3:ra24
41. Faouzi M, Hague F, Potier M, Ahidouch A, Sevestre H, Ouadid-Ahidouch H. 2011. Down-regulation of Orai3 arrests cell-cycle progression and induces apoptosis in breast cancer cells but not in normal breast epithelial cells. *J. Cell. Physiol.* 226:542–51
42. Faouzi M, Kischel P, Hague F, Ahidouch A, Benzerdjeb N, et al. 2013. ORAI3 silencing alters cell proliferation and cell cycle progression via c-myc pathway in breast cancer cells. *Biochim. Biophys. Acta Mol. Cell Res.* 1833:752–60
43. Motiani RK, Hyzinski-García MC, Zhang X, Henkel MM, Abdullaev IF, et al. 2013. STIM1 and Orai1 mediate CRAC channel activity and are essential for human glioblastoma invasion. *Pflügers Arch. Eur. J. Physiol.* 465:1249–60
44. Brandman O, Liou J, Park WS, Meyer T. 2007. STIM2 is a feedback regulator that stabilizes basal cytosolic and endoplasmic reticulum Ca<sup>2+</sup> levels. *Cell* 131:1327–39
45. Emrich SM, Yoast RE, Xin P, Arige V, Wagner LE, et al. 2021. Omnitemporal choreographies of all five STIM/Orai and IP<sub>3</sub>Rs underlie the complexity of mammalian Ca<sup>2+</sup> signaling. *Cell Rep.* 34:108760
46. Subedi KP, Ong HL, Son GY, Liu X, Ambudkar IS. 2018. STIM2 induces activated conformation of STIM1 to control Orai1 function in ER-PM junctions. *Cell Rep.* 23:522–34
47. Ong HL, de Souza LB, Zheng C, Cheng KT, Liu X, et al. 2015. STIM2 enhances receptor-stimulated Ca<sup>2+</sup> signaling by promoting recruitment of STIM1 to the endoplasmic reticulum-plasma membrane junctions. *Sci. Signal.* 8:ra3
48. Berna-Erro A, Braun A, Kraft R, Kleinschnitz C, Schuhmann MK, et al. 2009. STIM2 regulates capacitive Ca<sup>2+</sup> entry in neurons and plays a key role in hypoxic neuronal cell death. *Sci. Signal.* 2:ra67
49. Emrich SM, Yoast RE, Xin P, Zhang X, Pathak T, et al. 2019. Cross-talk between N-terminal and C-terminal domains in stromal interaction molecule 2 (STIM2) determines enhanced STIM2 sensitivity. *J. Biol. Chem.* 294:6318–32

50. Nelson HA, Leech CA, Kopp RF, Roe MW. 2018. Interplay between ER Ca<sup>2+</sup> binding proteins, STIM1 and STIM2, is required for store-operated Ca<sup>2+</sup> entry. *Int. J. Mol. Sci.* 19:1522
51. Miederer AM, Alansary D, Schwar G, Lee PH, Jung M, et al. 2015. A STIM2 splice variant negatively regulates store-operated calcium entry. *Nat. Commun.* 6:6899
52. Rana A, Yen M, Sadaghiani AM, Malmersjo S, Park CY, et al. 2015. Alternative splicing converts STIM2 from an activator to an inhibitor of store-operated calcium channels. *J. Cell Biol.* 209:653–69
53. Kim KM, Rana A, Park CY. 2019. Orai1 inhibitor STIM2 $\beta$  regulates myogenesis by controlling SOCE dependent transcriptional factors. *Sci. Rep.* 9:10794
54. Zhou Y, Nwokonko RM, Cai X, Loktionova NA, Abdulqadir R, et al. 2018. Cross-linking of Orai1 channels by STIM proteins. *PNAS* 115:E3398–407
55. Darbellay B, Arnaudeau S, Bader CR, Konig S, Bernheim L. 2011. STIM1L is a new actin-binding splice variant involved in fast repetitive Ca<sup>2+</sup> release. *J. Cell Biol.* 194:335–46
56. Ramesh G, Jarzembowski L, Schwarz Y, Poth V, Konrad M, et al. 2021. A short isoform of STIM1 confers frequency-dependent synaptic enhancement. *Cell Rep.* 34:108844
57. Vaeth M, Kahlfuss S, Feske S. 2020. CRAC channels and calcium signaling in T cell-mediated immunity. *Trends Immunol.* 41:878–901
58. Feske S, Wulff H, Skolnik EY. 2015. Ion channels in innate and adaptive immunity. *Annu. Rev. Immunol.* 33:291–353
59. Gwack Y, Srikanth S, Oh-Hora M, Hogan PG, Lamperti ED, et al. 2008. Hair loss and defective T- and B-cell function in mice lacking ORAI1. *Mol. Cell. Biol.* 28:5209–22
60. McCarl CA, Khalil S, Ma J, Oh-hora M, Yamashita M, et al. 2010. Store-operated Ca<sup>2+</sup> entry through ORAI1 is critical for T cell-mediated autoimmunity and allograft rejection. *J. Immunol.* 185:5845–58
61. Inayama M, Suzuki Y, Yamada S, Kurita T, Yamamura H, et al. 2015. Orai1–Orai2 complex is involved in store-operated calcium entry in chondrocyte cell lines. *Cell Calcium* 57:337–47
62. Scremini E, Agostini M, Leparulo A, Pozzan T, Greotti E, Fasolato C. 2020. ORAI2 down-regulation potentiates SOCE and decreases A $\beta$ 42 accumulation in human neuroglioma cells. *Int. J. Mol. Sci.* 21:5288
63. Desai PN, Zhang X, Wu S, Janoshazi A, Bolimuntha S, et al. 2015. Multiple types of calcium channels arising from alternative translation initiation of the Orai1 message. *Sci. Signal.* 8:ra74
64. Thompson JL, Mignen O, Shuttleworth TJ. 2013. The ARC channel—an endogenous store-independent Orai channel. *Curr. Top Membr.* 71:125–48
65. Zhang X, Zhang W, Gonzalez-Cobos JC, Jardin I, Romanin C, et al. 2014. Complex role of STIM1 in the activation of store-independent Orai1/3 channels. *J. Gen. Physiol.* 143:345–59
66. Ye Z, Shen Y, Jin K, Qiu J, Hu B, et al. 2021. Arachidonic acid-regulated calcium signaling in T cells from patients with rheumatoid arthritis promotes synovial inflammation. *Nat. Commun.* 12:907
67. Fuchs S, Rensing-Ehl A, Speckmann C, Bengsch B, Schmitt-Graeff A, et al. 2012. Antiviral and regulatory T cell immunity in a patient with stromal interaction molecule 1 deficiency. *J. Immunol.* 188:1523–33
68. Schaballie H, Rodriguez R, Martin E, Moens L, Frans G, et al. 2015. A novel hypomorphic mutation in STIM1 results in a late-onset immunodeficiency. *J. Allergy Clin. Immunol.* 136:816–19.e4
69. Pearce EL, Poffenberger MC, Chang CH, Jones RG. 2013. Fueling immunity: insights into metabolism and lymphocyte function. *Science* 342:1242454
70. Vaeth M, Maus M, Klein-Hessling S, Freinkman E, Yang J, et al. 2017. Store-operated Ca<sup>2+</sup> entry controls clonal expansion of T cells through metabolic reprogramming. *Immunity* 47:664–79.e6
71. Azzi JR, Sayegh MH, Mallat SG. 2013. Calcineurin inhibitors: 40 years later, can't live without. . . . *J. Immunol.* 191:5785–91
72. Golubovskaya V, Wu L. 2016. Different subsets of T cells, memory, effector functions, and CAR-T immunotherapy. *Cancers* 8:36
73. Wing JB, Lim EL, Sakaguchi S. 2020. Control of foreign Ag-specific Ab responses by Treg and Tfr. *Immunol. Rev.* 296:104–19
74. Linterman MA, Pierson W, Lee SK, Kallies A, Kawamoto S, et al. 2011. Foxp3<sup>+</sup> follicular regulatory T cells control the germinal center response. *Nat. Med.* 17:975–82
75. Vaeth M, Eckstein M, Shaw PJ, Kozhaya L, Yang J, et al. 2016. Store-operated Ca<sup>2+</sup> entry in follicular T cells controls humoral immune responses and autoimmunity. *Immunity* 44:1350–64

76. Oh-Hora M, Yamashita M, Hogan PG, Sharma S, Lamperti E, et al. 2008. Dual functions for the endoplasmic reticulum calcium sensors STIM1 and STIM2 in T cell activation and tolerance. *Nat. Immunol.* 9:432–43
77. Greimers R, Trebak M, Moutschen M, Jacobs N, Boniver J. 1996. Improved four-color flow cytometry method using fluo-3 and triple immunofluorescence for analysis of intracellular calcium ion ( $[Ca^{2+}]_i$ ) fluxes among mouse lymph node B- and T-lymphocyte subsets. *Cytometry* 23:205–17
78. Kircher S, Merino-Wong M, Niemeyer BA, Alansary D. 2018. Profiling calcium signals of *in vitro* polarized human effector CD4<sup>+</sup> T cells. *Biochim. Biophys. Acta Mol. Cell Res.* 1865:932–43
79. Vaeth M, Wang YH, Eckstein M, Yang J, Silverman GJ, et al. 2019. Tissue resident and follicular Treg cell differentiation is regulated by CRAC channels. *Nat. Commun.* 10:1183
80. Oh-Hora M, Lu X, Shiokawa M, Takayanagi H, Yamasaki S. 2019. Stromal interaction molecule deficiency in T cells promotes spontaneous follicular helper T cell development and causes type 2 immune disorders. *J. Immunol.* 202:2616–27
81. Tesmer LA, Lundy SK, Sarkar S, Fox DA. 2008. Th17 cells in human disease. *Immunol. Rev.* 223:87–113
82. Kim KD, Srikanth S, Tan YV, Yee MK, Jew M, et al. 2014. Calcium signaling via Orai1 is essential for induction of the nuclear orphan receptor pathway to drive Th17 differentiation. *J. Immunol.* 192:110–22
83. Ma J, McCarl CA, Khalil S, Lüthy K, Feske S. 2010. T-cell-specific deletion of STIM1 and STIM2 protects mice from EAE by impairing the effector functions of Th1 and Th17 cells. *Eur. J. Immunol.* 40:3028–42
84. Kaufmann U, Kahlfuss S, Yang J, Ivanova E, Koralov SB, Feske S. 2019. Calcium signaling controls pathogenic Th17 cell-mediated inflammation by regulating mitochondrial function. *Cell Metab.* 29:1104–18.e6
85. Matsumoto M, Fujii Y, Baba A, Hikida M, Kurosaki T, Baba Y. 2011. The calcium sensors STIM1 and STIM2 control B cell regulatory function through interleukin-10 production. *Immunity* 34:703–14
86. Tang H, Wang H, Lin Q, Fan F, Zhang F, et al. 2017. Loss of IP<sub>3</sub> receptor-mediated Ca<sup>2+</sup> release in mouse B cells results in abnormal B cell development and function. *J. Immunol.* 199:570–80
87. Akkaya M, Pierce SK. 2019. From zero to sixty and back to zero again: the metabolic life of B cells. *Curr. Opin. Immunol.* 57:1–7
88. Berry CT, Liu X, Myles A, Nandi S, Chen YH, et al. 2020. BCR-induced Ca<sup>2+</sup> signals dynamically tune survival, metabolic reprogramming, and proliferation of naive B cells. *Cell Rep.* 31:107474
89. Akkaya M, Traba J, Roesler AS, Miozzo P, Akkaya B, et al. 2018. Second signals rescue B cells from activation-induced mitochondrial dysfunction and death. *Nat. Immunol.* 19:871–84
90. Luo W, Weisel F, Shlomchik MJ. 2018. B cell receptor and CD40 signaling are rewired for synergistic induction of the c-Myc transcription factor in germinal center B cells. *Immunity* 48:313–26.e5
91. Weisel FJ, Mullett SJ, Elsner RA, Menk AV, Trivedi N, et al. 2020. Germinal center B cells selectively oxidize fatty acids for energy while conducting minimal glycolysis. *Nat. Immunol.* 21:331–42
92. Maus M, Cuk M, Patel B, Lian J, Ouimet M, et al. 2017. Store-operated Ca<sup>2+</sup> entry controls induction of lipolysis and the transcriptional reprogramming to lipid metabolism. *Cell Metab.* 25:698–712
93. Demarex N, Saul S. 2018. The role of STIM proteins in neutrophil functions. *J. Physiol.* 596:2699–708
94. Vig M, DeHaven WI, Bird GS, Billingsley JM, Wang H, et al. 2008. Defective mast cell effector functions in mice lacking the CRACM1 pore subunit of store-operated calcium release-activated calcium channels. *Nat. Immunol.* 9:89–96
95. Grimes D, Johnson R, Pashos M, Cummings C, Kang C, et al. 2020. ORAI1 and ORAI2 modulate murine neutrophil calcium signaling, cellular activation, and host defense. *PNAS* 117:24403–14
96. Vaeth M, Zee I, Concepcion AR, Maus M, Shaw P, et al. 2015. Ca<sup>2+</sup> signaling but not store-operated Ca<sup>2+</sup> entry is required for the function of macrophages and dendritic cells. *J. Immunol.* 195:1202–17
97. Freund-Brown J, Choa R, Singh BK, Robertson TF, Ferry GM, et al. 2017. Cutting edge: murine NK cells degranulate and retain cytotoxic function without store-operated calcium entry. *J. Immunol.* 199:1973–78
98. Srikanth S, Woo JS, Wu B, El-Sherbiny YM, Leung J, et al. 2019. The Ca<sup>2+</sup> sensor STIM1 regulates the type I interferon response by retaining the signaling adaptor STING at the endoplasmic reticulum. *Nat. Immunol.* 20:152–62

99. Nunes-Hasler P, Maschalidi S, Lippens C, Castelbou C, Bouvet S, et al. 2017. STIM1 promotes migration, phagosomal maturation and antigen cross-presentation in dendritic cells. *Nat. Commun.* 8:1852
100. Shinde AV, Motiani RK, Zhang X, Abdullaev IF, Adam AP, et al. 2013. STIM1 controls endothelial barrier function independently of Orai1 and Ca<sup>2+</sup> entry. *Sci. Signal.* 6:ra18
101. Chauhan AS, Liu X, Jing J, Lee H, Yadav RK, et al. 2019. STIM2 interacts with AMPK and regulates calcium-induced AMPK activation. *FASEB J.* 33:2957–70
102. Thillaiappan NB, Chavda AP, Tovey SC, Prole DL, Taylor CW. 2017. Ca<sup>2+</sup> signals initiate at immobile IP<sub>3</sub> receptors adjacent to ER-plasma membrane junctions. *Nat. Commun.* 8:1505
103. Sampieri A, Santoyo K, Asanov A, Vaca L. 2018. Association of the IP<sub>3</sub>R to STIM1 provides a reduced intraluminal calcium microenvironment, resulting in enhanced store-operated calcium entry. *Sci. Rep.* 8:13252
104. Lang F, Münzer P, Gawaz M, Borst O. 2013. Regulation of STIM1/Orai1-dependent Ca<sup>2+</sup> signalling in platelets. *Thrombos. Haemostas.* 110:925–30
105. Gilio K, van Kruchten R, Braun A, Berna-Erro A, Feijge MA, et al. 2010. Roles of platelet STIM1 and Orai1 in glycoprotein VI- and thrombin-dependent procoagulant activity and thrombus formation. *J. Biol. Chem.* 285:23629–38
106. Braun A, Varga-Szabo D, Kleinschnitz C, Pleines I, Bender M, et al. 2009. Orai1 (CRACM1) is the platelet SOC channel and essential for pathological thrombus formation. *Blood* 113:2056–63
107. Varga-Szabo D, Braun A, Kleinschnitz C, Bender M, Pleines I, et al. 2008. The calcium sensor STIM1 is an essential mediator of arterial thrombosis and ischemic brain infarction. *J. Exp. Med.* 205:1583–91
108. Markello T, Chen D, Kwan JY, Horkayne-Szakaly I, Morrison A, et al. 2015. York platelet syndrome is a CRAC channelopathy due to gain-of-function mutations in STIM1. *Mol. Genet. Metab.* 114:474–82
109. Morin G, Bruechle NO, Singh AR, Knopp C, Jedraszak G, et al. 2014. Gain-of-function mutation in STIM1 (P.R304W) is associated with Stormorken syndrome. *Hum. Mutat.* 35:1221–32
110. Misceo D, Holmgren A, Louch WE, Holme PA, Mizobuchi M, et al. 2014. A dominant STIM1 mutation causes Stormorken syndrome. *Hum. Mutat.* 35:556–64
111. Nesin V, Wiley G, Kousi M, Ong EC, Lehmann T, et al. 2014. Activating mutations in *STIM1* and *ORAI1* cause overlapping syndromes of tubular myopathy and congenital miosis. *PNAS* 111:4197–202
112. Fahrner M, Stadlbauer M, Muik M, Rathner P, Stathopoulos P, et al. 2018. A dual mechanism promotes switching of the Stormorken STIM1 R304W mutant into the activated state. *Nat. Commun.* 9:825
113. Böhm J, Chevessier F, Maues De Paula A, Koch C, Attarian S, et al. 2013. Constitutive activation of the calcium sensor STIM1 causes tubular-aggregate myopathy. *Am. J. Hum. Genet.* 92:271–78
114. Grosse J, Braun A, Varga-Szabo D, Beyersdorf N, Schneider B, et al. 2007. An EF hand mutation in Stim1 causes premature platelet activation and bleeding in mice. *J. Clin. Investig.* 117:3540–50
115. Cordero-Sanchez C, Riva B, Reano S, Clemente N, Zaggia I, et al. 2019. A luminal EF-hand mutation in STIM1 in mice causes the clinical hallmarks of tubular aggregate myopathy. *Dis. Models Mech.* 13:dmm041111
116. Gamage TH, Gunnes G, Lee RH, Louch WE, Holmgren A, et al. 2018. STIM1 R304W causes muscle degeneration and impaired platelet activation in mice. *Cell Calcium* 76:87–100
117. Silva-Rojas R, Treves S, Jacobs H, Kessler P, Messaddeq N, et al. 2019. STIM1 over-activation generates a multi-systemic phenotype affecting the skeletal muscle, spleen, eye, skin, bones and immune system in mice. *Hum. Mol. Genet.* 28:1579–93
118. Eckstein M, Aulestia FJ, Nurbaeva MK, Lacruz RS. 2018. Altered Ca<sup>2+</sup> signaling in enamelopathies. *Biochim. Biophys. Acta Mol. Cell Res.* 1865:1778–85
119. Paine ML, Snead ML. 2005. Tooth developmental biology: disruptions to enamel-matrix assembly and its impact on biomineralization. *Orthodont. Craniofac. Res.* 8:239–51
120. Baranova J, Büchner D, Götz W, Schulze M, Tobiasch E. 2020. Tooth formation: Are the hardest tissues of human body hard to regenerate? *Int. J. Mol. Sci.* 21:4031
121. Lacruz RS, Smith CE, Bringas P Jr., Chen YB, Smith SM, et al. 2012. Identification of novel candidate genes involved in mineralization of dental enamel by genome-wide transcript profiling. *J. Cell. Physiol.* 227:2264–75
122. Nurbaeva MK, Eckstein M, Concepcion AR, Smith CE, Srikanth S, et al. 2015. Dental enamel cells express functional SOCE channels. *Sci. Rep.* 5:15803

123. Eckstein M, Vaeth M, Fornai C, Vinu M, Bromage TG, et al. 2017. Store-operated  $\text{Ca}^{2+}$  entry controls ameloblast cell function and enamel development. *JCI Insight* 2:e91166
124. Furukawa Y, Haruyama N, Nikaido M, Nakanishi M, Ryu N, et al. 2017. Stim1 regulates enamel mineralization and ameloblast modulation. *J. Dent. Res.* 96:1422–29
125. Berg J, Yang H, Jan LY. 2012.  $\text{Ca}^{2+}$ -activated  $\text{Cl}^-$  channels at a glance. *J. Cell Sci.* 125:1367–71
126. Concepcion AR, Vaeth M, Wagner LE 2nd, Eckstein M, Hecht L, et al. 2016. Store-operated  $\text{Ca}^{2+}$  entry regulates  $\text{Ca}^{2+}$ -activated chloride channels and eccrine sweat gland function. *J. Clin. Investig.* 126:4303–18
127. King J, Petranka JG, Davis FM, Desai PN, Putney JW, Bird GS. 2014. Role of Orai1 and store-operated calcium entry in mouse lacrimal gland signalling and function. *J. Physiol.* 592:927–39
128. Davis FM, Janoshazi A, Janardhan KS, Steinckwich N, D'Agostin DM, et al. 2015. Essential role of Orai1 store-operated calcium channels in lactation. *PNAS* 112:5827–32
129. Davis FM, Goulding EH, D'Agostin DM, Janardhan KS, Cummings CA, et al. 2016. Male infertility in mice lacking the store-operated  $\text{Ca}^{2+}$  channel Orai1. *Cell Calcium* 59:189–97
130. Mosinger B, Redding KM, Parker MR, Yevshayeva V, Yee KK, et al. 2013. Genetic loss or pharmacological blockade of testes-expressed taste genes causes male sterility. *PNAS* 110:12319–24
131. Ahuja M, Schwartz DM, Tandon M, Son A, Zeng M, et al. 2017. Orai1-mediated antimicrobial secretion from pancreatic acini shapes the gut microbiome and regulates gut innate immunity. *Cell Metab.* 25:635–46
132. Michelucci A, Garcia-Castaneda M, Boncompagni S, Dirksen RT. 2018. Role of STIM1/ORAI1-mediated store-operated  $\text{Ca}^{2+}$  entry in skeletal muscle physiology and disease. *Cell Calcium* 76:101–15
133. Trebak M, Zhang W, Ruhle B, Henkel MM, Gonzalez-Cobos JC, et al. 2013. What role for store-operated  $\text{Ca}^{2+}$  entry in muscle? *Microcirculation* 20:330–36
134. Feske S. 2010. CRAC channelopathies. *Pflügers Arch. Eur. J. Physiol.* 460:417–35
135. Potier M, Gonzalez JC, Motiani RK, Abdullaev IF, Bisailon JM, et al. 2009. Evidence for STIM1- and Orai1-dependent store-operated calcium influx through ICRAC in vascular smooth muscle cells: role in proliferation and migration. *FASEB J* 23:2425–37
136. Trebak M. 2012. STIM/Orai signalling complexes in vascular smooth muscle. *J. Physiol.* 590:4201–8
137. Zhang W, Halligan KE, Zhang X, Bisailon JM, Gonzalez-Cobos JC, et al. 2011. Orai1-mediated I (CRAC) is essential for neointima formation after vascular injury. *Circ. Res.* 109:534–42
138. Zhao G, Li T, Brochet DX, Rosenberg PB, Lederer WJ. 2015. STIM1 enhances SR  $\text{Ca}^{2+}$  content through binding phospholamban in rat ventricular myocytes. *PNAS* 112:E4792–801
139. Cacheux M, Strauss B, Raad N, Ilkan Z, Hu J, et al. 2019. Cardiomyocyte-specific STIM1 (stromal interaction molecule 1) depletion in the adult heart promotes the development of arrhythmogenic discordant alternans. *Circ. Arrhythm. Electrophysiol.* 12:e007382
140. Collins HE, He L, Zou L, Qu J, Zhou L, et al. 2014. Stromal interaction molecule 1 is essential for normal cardiac homeostasis through modulation of ER and mitochondrial function. *Am. J. Physiol. Heart Circ. Physiol.* 306:H1231–39
141. Benard L, Oh JG, Cacheux M, Lee A, Nonnenmacher M, et al. 2016. Cardiac Stim1 silencing impairs adaptive hypertrophy and promotes heart failure through inactivation of mTORC2/Akt signaling. *Circulation* 133:1458–71
142. Mancarella S, Potireddy S, Wang Y, Gao H, Gandhirajan RK, et al. 2013. Targeted STIM deletion impairs calcium homeostasis, NFAT activation, and growth of smooth muscle. *FASEB J.* 27:893–906
143. Kassan M, Ait-Aissa K, Radwan E, Mali V, Haddox S, et al. 2016. Essential role of smooth muscle STIM1 in hypertension and cardiovascular dysfunction. *Arterioscler. Thromb. Vasc. Biol.* 36:1900–9
144. Kassan M, Zhang W, Aissa KA, Stolwijk J, Trebak M, Matrougui K. 2015. Differential role for stromal interacting molecule 1 in the regulation of vascular function. *Pflügers Arch. Eur. J. Physiol.* 467:1195–202
145. Zheng H, Drumm BT, Earley S, Sung TS, Koh SD, Sanders KM. 2018. SOCE mediated by STIM and Orai is essential for pacemaker activity in the interstitial cells of Cajal in the gastrointestinal tract. *Sci. Signal.* 11:eaq0918
146. Johnson M, Trebak M. 2019. ORAI channels in cellular remodeling of cardiorespiratory disease. *Cell Calcium* 79:1–10

147. Bartoli F, Bailey MA, Rode B, Mateo P, Antigny F, et al. 2020. Orai1 channel inhibition preserves left ventricular systolic function and normal Ca<sup>2+</sup> handling after pressure overload. *Circulation* 141:199–216
148. Hulot JS, Fauconnier J, Ramanujam D, Chaanine A, Aubart F, et al. 2011. Critical role for stromal interaction molecule 1 in cardiac hypertrophy. *Circulation* 124:796–805
149. Correll RN, Goonasekera SA, van Berlo JH, Burr AR, Accornero F, et al. 2015. STIM1 elevation in the heart results in aberrant Ca<sup>2+</sup> handling and cardiomyopathy. *J. Mol. Cell. Cardiol.* 87:38–47
150. Johnson MT, Gudlur A, Zhang X, Xin P, Emrich SM, et al. 2020. L-type Ca<sup>2+</sup> channel blockers promote vascular remodeling through activation of STIM proteins. *PNAS* 117:17369–80
151. Spinelli AM, Gonzalez-Cobos JC, Zhang X, Motiani RK, Rowan S, et al. 2012. Airway smooth muscle STIM1 and Orai1 are upregulated in asthmatic mice and mediate PDGF-activated SOCE, CRAC currents, proliferation, and migration. *Pflügers Arch. Eur. J. Physiol.* 464:481–92
152. Collins SR, Meyer T. 2011. Evolutionary origins of STIM1 and STIM2 within ancient Ca<sup>2+</sup> signaling systems. *Trends Cell Biol.* 21:202–11
153. Gammons J, Trebak M, Mancarella S. 2021. Cardiac-specific deletion of Orai3 leads to severe dilated cardiomyopathy and heart failure in mice. *J. Am. Heart Assoc.* 10:e019486
154. Saliba Y, Keck M, Marchand A, Atassi F, Ouille A, et al. 2015. Emergence of Orai3 activity during cardiac hypertrophy. *Cardiovasc. Res.* 105:248–59
155. Gonzalez-Cobos JC, Zhang X, Zhang W, Ruhle B, Motiani RK, et al. 2013. Store-independent Orai1/3 channels activated by intracrine leukotriene C4: role in neointimal hyperplasia. *Circ. Res.* 112:1013–25
156. Zhang W, Zhang X, Gonzalez-Cobos JC, Stolwijk JA, Matrougui K, Trebak M. 2015. Leukotriene-C4 synthase, a critical enzyme in the activation of store-independent Orai1/Orai3 channels, is required for neointimal hyperplasia. *J. Biol. Chem.* 290:5015–27
157. Moccia F, Zuccolo E, Soda T, Tanzi F, Guerra G, et al. 2015. Stim and Orai proteins in neuronal Ca<sup>2+</sup> signaling and excitability. *Front. Cell. Neurosci.* 9:153
158. Sun S, Zhang H, Liu J, Popugaeva E, Xu NJ, et al. 2014. Reduced synaptic STIM2 expression and impaired store-operated calcium entry cause destabilization of mature spines in mutant presenilin mice. *Neuron* 82:79–93
159. Stegner D, Hofmann S, Schuhmann MK, Kraft P, Herrmann AM, et al. 2019. Loss of Orai2-mediated capacitative Ca<sup>2+</sup> entry is neuroprotective in acute ischemic stroke. *Stroke* 50:3238–45
160. Hartmann J, Karl RM, Alexander RP, Adelsberger H, Brill MS, et al. 2014. STIM1 controls neuronal Ca<sup>2+</sup> signaling, mGluR1-dependent synaptic transmission, and cerebellar motor behavior. *Neuron* 82:635–44
161. Chen-Engerer HJ, Hartmann J, Karl RM, Yang J, Feske S, Konnerth A. 2019. Two types of functionally distinct Ca<sup>2+</sup> stores in hippocampal neurons. *Nat. Commun.* 10:3223
162. Maneshi MM, Toth AB, Ishii T, Hori K, Tsujikawa S, et al. 2020. Orai1 channels are essential for amplification of glutamate-evoked Ca<sup>2+</sup> signals in dendritic spines to regulate working and associative memory. *Cell Rep.* 33:108464
163. Dou Y, Xia J, Gao R, Gao X, Munoz FM, et al. 2018. Orai1 plays a crucial role in central sensitization by modulating neuronal excitability. *J. Neurosci.* 38:887–900
164. Maciag F, Majewski Ł, Boguszewski PM, Gupta RK, Wasilewska I, et al. 2019. Behavioral and electrophysiological changes in female mice overexpressing ORAI1 in neurons. *Biochim. Biophys. Acta Mol. Cell Res.* 1866:1137–50
165. Garcia-Alvarez G, Shetty MS, Lu B, Yap KA, Oh-Hora M, et al. 2015. Impaired spatial memory and enhanced long-term potentiation in mice with forebrain-specific ablation of the Stim genes. *Front. Behav. Neurosci.* 9:180
166. Garcia-Alvarez G, Lu B, Yap KA, Wong LC, Thevathasan JV, et al. 2015. STIM2 regulates PKA-dependent phosphorylation and trafficking of AMPARs. *Mol. Biol. Cell* 26:1141–59
167. Dittmer PJ, Wild AR, Dell'Acqua ML, Sather WA. 2017. STIM1 Ca<sup>2+</sup> sensor control of L-type Ca<sup>2+</sup>-channel-dependent dendritic spine structural plasticity and nuclear signaling. *Cell Rep.* 19:321–34
168. Volterra A, Liaudet N, Savtchouk I. 2014. Astrocyte Ca<sup>2+</sup> signalling: an unexpected complexity. *Nat. Rev. Neurosci.* 15:327–35
169. Kwon J, An H, Sa M, Won J, Shin JI, Lee CJ. 2017. Orai1 and Orai3 in combination with Stim1 mediate the majority of store-operated calcium entry in astrocytes. *Exp. Neurobiol.* 26:42–54

170. Gao X, Xia J, Munoz FM, Manners MT, Pan R, et al. 2016. STIMs and Orai1 regulate cytokine production in spinal astrocytes. *J. Neuroinflamm.* 13:126
171. Michaelis M, Nieswandt B, Stegner D, Eilers J, Kraft R. 2015. STIM1, STIM2, and Orai1 regulate store-operated calcium entry and purinergic activation of microglia. *Glia* 63:652–63
172. Heo DK, Lim HM, Nam JH, Lee MG, Kim JY. 2015. Regulation of phagocytosis and cytokine secretion by store-operated calcium entry in primary isolated murine microglia. *Cell. Signal.* 27:177–86
173. Toth AB, Hori K, Novakovic MM, Bernstein NG, Lambot L, Prakriya M. 2019. CRAC channels regulate astrocyte  $\text{Ca}^{2+}$  signaling and gliotransmitter release to modulate hippocampal GABAergic transmission. *Sci. Signal.* 12:eaaw5450